



- (51) International Patent Classification:
C12Q 1/68 (2006.01)
- (21) International Application Number:
PCT/US2015/061615
- (22) International Filing Date:
19 November 2015 (19.11.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/082,883 21 November 2014 (21.11.2014) US
- (71) Applicant: NANOSTRING TECHNOLOGIES, INC.
[US/US]; 530 Fairview Avenue North, Suite 2000, Seattle,
Washington 98109 (US).
- (72) Inventors: BEECHEM, Joseph M.; 46 Ridgeline Drive,
Eugene, Oregon 97405 (US). KHAFIZOV, Rustem; 1200
Mercer Street, Apt. 212, Seattle, Washington 98109 (US).
- (74) Agents: PAVAO, Matthew et al.; Cooley LLP, 1299
Pennsylvania Avenue, NW, Suite 700, Washington, Dis-
trict of Columbia 20004 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: ENZYME- AND AMPLIFICATION-FREE SEQUENCING

Figure 1





Figure 2



(57) Abstract: The present invention relates to sequencing probes, methods, kits, and apparatuses that provide enzyme-free, amplification-free, and library-free nucleic acid sequencing that has long-read-lengths and with low error rate. A sequencing probe is used comprising a target binding domain and a barcode domain; wherein said target binding domain comprises at least four nucleotides and is capable of binding a target nucleic acid; wherein said barcode domain comprises a synthetic backbone, said barcode domain comprising at least a first attachment region, said first attachment region comprising a nucleic acid sequence capable of being bound by a first complementary nucleic acid molecule and wherein said nucleic acid sequence of said first attachment region determines the position and identity of a first nucleotide in said target nucleic acid that is bound by a first nucleotide of said target binding domain.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). **Published:**

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

ENZYME- AND AMPLIFICATION-FREE SEQUENCING

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/082,883, filed November 21, 2014. The contents of the aforementioned patent application are incorporated herein by reference in their entireties.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on November 19, 2015, is named NATE-025_ST25.txt and is 20,860 bytes in size.

BACKGROUND OF THE INVENTION

[0003] There are currently a variety of methods for nucleic acid sequencing, *i.e.*, the process of determining the precise order of nucleotides within a nucleic acid molecule. Current methods require amplifying a nucleic acid enzymatically, *e.g.*, PCR, and/or by cloning. Further enzymatic polymerizations are required to produce a detectable signal by a light detection means. Such amplification and polymerization steps are costly and/or time-consuming. Thus, there is a need in the art for a method of nucleic acid sequencing that is amplification- and enzyme-free. The present invention addresses these needs.

SUMMARY OF THE INVENTION

[0004] The present invention provides sequencing probes, methods, kits, and apparatuses that provide enzyme-free, amplification-free, and library-free nucleic acid sequencing that has long-read-lengths and with low error rate. Moreover, the methods, kits, and apparatuses have rapid sample-to-answer capability. These features are particularly useful for sequencing in a clinical setting.

[0005] Provided herein are sequencing probes comprising a target binding domain and a barcode domain. The target binding domain and the barcode domain may be operably linked, *e.g.*, covalently linked. A sequencing probe optionally comprises a spacer between the target binding domain and the barcode domain. The spacer can be any polymer with appropriate mechanical

properties, for example, a single- or double-stranded DNA spacer (of 1 to 100 nucleotides, e.g., 2 to 50 nucleotides). Non-limiting examples of double-stranded DNA spacers include the sequences covered by SEQ ID NO: 25 to SEQ ID NO: 29.

[0006] The target binding domain comprises at least four nucleotides (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, or more) and is capable of binding a target nucleic acid (e.g., DNA, RNA, and PNA). The barcode domain comprises a synthetic backbone, the barcode domain having at least a first position which comprises one or more attachment regions. The barcode domain may have one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or more positions; each position having one or more (e.g., one to fifty) attachment regions; each attachment region comprises at least one (*i.e.*, one to fifty, e.g., ten to thirty copies of a nucleic acid sequence(s)) capable of reversibly binding to a complementary nucleic acid molecule (RNA or DNA). Certain positions in a barcode domain may have more attachment regions than other positions; alternately, each position in a barcode domain has the same number of attachment regions. The nucleic acid sequence of a first attachment region determines the position and identity of a first nucleotide in the target nucleic acid that is bound by a first nucleotide of the target binding domain, whereas the nucleic acid sequence of a second attachment region determines the position and identity of a second nucleotide in the target nucleic acid that is bound by a second nucleotide of the target binding domain. Likewise, the nucleic acid sequence of a sixth attachment region determines the position and identity of a sixth nucleotide in the target nucleic acid that is bound by a sixth nucleotide of the target binding domain. In embodiments, the synthetic backbone comprises a polysaccharide, a polynucleotide (e.g., single or double stranded DNA or RNA), a peptide, a peptide nucleic acid, or a polypeptide. The number of nucleotides in a target binding domain equals to or is greater than (e.g., 1, 2, 3, 4, or more) the number of positions in the barcode domain. Each attachment region in a specific position of the barcode domain may include one copy of the same nucleic acid sequence and/or multiple copies of the same nucleic acid sequence. However, an attachment region will include a different nucleic acid sequence than an attachment region in a different position of the barcode domain, even when both attachment regions identify the same type of nucleotide, e.g., adenine, thymine, cytosine, guanine, uracil, and analogs thereof. An attachment region may be linked to a modified monomer, e.g., a modified nucleotide, in the synthetic backbone, thereby creating a branch relative to the backbone. An attachment region may be part of a synthetic backbone's polynucleotide

sequence. One or more attachment regions may be adjacent to at least one flanking single-stranded polynucleotide, that is, an attachment region may be operably linked to a 5' flanking single-stranded polynucleotide and/or to a 3' flanking single-stranded polynucleotide. An attachment region with or without one or two flanking single-stranded polynucleotides may be hybridized to a hybridizing nucleic acid molecule lacking a detectable label. A hybridizing nucleic acid molecule lacking a detectable label may be between about 4 and about 20 nucleotides in length, e.g., 12 nucleotides, or longer.

[0007] An attachment region may be bound by a complementary nucleic acid comprising a detectable label. Each complementary nucleic acid may comprise a detectable label.

[0008] Alternately, an attachment region may be bound by a complementary nucleic acid that is part of a reporter complex (comprising detectable labels). A complementary nucleic acid (either comprising a detectable label or of a reporter complex) may be between about 4 and about 20 nucleotides in length, e.g., about 8, 10, 12, and 14 nucleotides, or more. In a reporter complex, a complementary nucleic acid is linked (directly or indirectly) to a primary nucleic acid molecule. A complementary nucleic acid may be indirectly linked to a primary nucleic acid molecule via a single or double-stranded nucleic acid linker (e.g., a polynucleotide comprising 1 to 100 nucleotides). A primary nucleic acid is hybridized to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) secondary nucleic acids. Each secondary nucleic acid is hybridized to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) tertiary nucleic acids; the tertiary nucleic acids comprise one or more detectable labels. A or each secondary nucleic acid may comprise a region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule (an "extra-handle"); this region may be four or more (e.g., about 6 to about 40, e.g., about 8, 10, 12, and 14) nucleotides in length. The region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule may comprise the nucleotide sequence of the complementary nucleic acid molecule that is linked to the primary nucleic acid molecule. This region may be located near the end of the secondary nucleic acid distal to its end that hybridizes to the primary nucleic acid. By having "extra-handles" comprising the nucleotide sequence of the complementary nucleic acid, the likelihood and speed at which a reporter complex binds to a sequencing probe is greatly increased. In any embodiment or aspect of the present invention, when a reporter complex comprises "extra-handles", the reporter complex can hybridize to a sequencing probe either via the reporter

complex's complementary nucleic acid or via the "extra-handle." Thus, for example, the phrase "binding to the first attachment region . . . a first complementary nucleic acid molecule of a first reporter complex" would be understood according to its plain meaning and also understood to mean "binding to the first attachment region . . . an 'extra handle' of a first reporter complex."

[0009] In embodiments, the terms "barcode domain" and "synthetic backbone" are synonymous.

[0010] Provided herein is a method for sequencing a nucleic acid using a sequencing probe of the present invention. The method comprises steps of: (1) hybridizing at least one sequencing probe, of the present invention, to an target nucleic acid that is immobilized (*e.g.*, at one, two, three, four, five, six, seven, eight, nine, ten or more positions) to a substrate; (2) binding to the first attachment region a first complementary nucleic acid molecule (RNA or DNA) which has a detectable label (*e.g.*, a fluorescent label) or a first complementary nucleic acid molecule of a first reporter complex comprising detectable labels (*e.g.*, fluorescent labels); (3) detecting the detectable label(s), and (4) identifying the position and identity of the first nucleotide in the immobilized target nucleic acid. Optionally, the immobilized target nucleic acid is elongated prior to being bound by the probe. The method further comprises steps of: (5) contacting the first attachment region (with or without one or two flanking single-stranded polynucleotides) with a first hybridizing nucleic acid molecule lacking a detectable label, thereby unbinding the first complementary nucleic acid molecule having a detectable label or the first complementary nucleic acid molecule of a first reporter complex comprising detectable labels and binding to, at least, the first attachment region a first hybridizing nucleic acid lacking a detectable label; (6) binding to the second attachment region a second complementary nucleic acid molecule having a detectable label or a complementary nucleic acid molecule of a second reporter complex comprising detectable labels; (7) detecting the detectable label(s); and (8) identifying the position and identity of the second nucleotide in the immobilized target nucleic acid. Steps (5) to (8) are repeated until each nucleotide in the immobilized target nucleic acid and corresponding to the target binding domain has been identified. Steps (5) and (6) may occur concurrently or sequentially. Each (*e.g.*, first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or higher) complementary nucleic acid molecule (having a detectable label or part of a reporter complex) has the same nucleic acid sequence as its corresponding (*i.e.*, first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or higher) hybridizing nucleic acid molecule lacking a detectable label. The target nucleic acid is immobilized to a substrate by binding a first

position and/or second position of the target nucleic acid with a first and/or a second capture probe; each capture probe comprises an affinity tag that selectively binds to a substrate. The first and/or second positions may be at or near a terminus of a target nucleic acid. The substrate can be any solid support known in the art, *e.g.*, a coated slide and microfluidic device (*e.g.*, coated with streptavidin). Other positions which are located distant from a terminus of a target nucleic acid may be selectively bound to the substrate. The nucleic acid may be elongated by applying a force (*e.g.*, gravity, hydrodynamic force, electromagnetic force, flow-stretching, a receding meniscus technique, and combinations thereof) sufficient to extend the target nucleic acid.

[0011] Provided herein is a method for sequencing a nucleic acid using one population of probes of the present invention or a plurality of populations of probes of the present invention. The method comprises steps of: (1) hybridizing a first population of sequencing probes (of the present invention) to a target nucleic acid that is immobilized to a substrate (with each sequencing probe in the first population de-hybridizing from the immobilized target nucleic acid under about the same conditions, *e.g.*, level of chaotropic agent, temperature, salt concentration, pH, and hydrodynamic force); (2) binding a plurality of first complementary nucleic acid molecules each having a detectable label or a plurality of first complementary nucleic acid molecules of a plurality of first reporter complexes each complex comprising detectable labels to a first attachment region in each sequencing probe in the first population; (3) detecting the detectable label(s); (4) identifying the position and identity of a plurality of first nucleotides in the immobilized target nucleic acid hybridized by sequencing probes in the first population; (5) contacting each first attachment region of each sequencing probe of the first population with a plurality of first hybridizing nucleic acid molecules lacking a detectable label thereby unbinding the first complementary nucleic acid molecules having a detectable label or of a reporter complex and binding to each first attachment region a first hybridizing nucleic acid molecule lacking a detectable label (6) binding a plurality of second complementary nucleic acid molecules each having a detectable label or a plurality of second complementary nucleic acid molecules of a plurality of second reporter complexes each complex comprising detectable labels to a second attachment region in each sequencing probe in the first population; (7) detecting the detectable label(s); and (8) identifying the position and identity of a plurality of second nucleotides in the immobilized target nucleic acid hybridized by sequencing probes in the first population. In step (9), steps (5) to (8) are repeated until each nucleotide in the immobilized

target nucleic acid and corresponding to the target binding domain of each sequencing probe in the first population has been identified. Steps (5) and (6) may occur concurrently or sequentially. Thereby, the linear order of nucleotides is identified for regions of the immobilized target nucleic acid that were hybridized by the target binding domain of sequencing probes in the first population of sequencing probes.

[0012] In embodiments, when a plurality of populations (i.e., more than one population) of probes are used, the method further comprises steps of: (10) de-hybridizing each sequencing probe of the first population from the nucleic acid; (11) removing each de-hybridized sequencing probe of the first population; (12) hybridizing at least a second population of sequencing probes of the present invention, where each sequencing probe in the second population de-hybridizes from the immobilized target nucleic acid under about the same conditions and de-hybridizes from the immobilized target nucleic acid under different conditions from the sequencing probes in the first population; (13) binding a plurality of first complementary nucleic acid molecules each having a detectable label or a plurality of first complementary nucleic acid molecules of a plurality of first reporter complexes each complex comprising detectable labels to a first attachment region in each sequencing probe in the second population; (14) detecting the detectable label(s) (15) identifying the position and identity of a plurality of first nucleotides in the immobilized target nucleic acid hybridized by sequencing probes in the second population; (16) contacting each first attachment region of each sequencing probe of the second population with a plurality of first hybridizing nucleic acid molecules lacking a detectable label thereby unbinding the first complementary nucleic acid molecules (having a detectable label or from a reporter complex) and binding to each first attachment region a first hybridizing nucleic acid molecule lacking detectable label; (17) binding a plurality of second complementary nucleic acid molecules each having a detectable label or a plurality of second complementary nucleic acid molecules of a plurality of second reporter complexes each complex comprising detectable labels to a second attachment region in each sequencing probe in the second population; (18) detecting the detectable label(s); (19) identifying the position and identity of a plurality of second nucleotides in the immobilized target nucleic acid hybridized by sequencing probes in the second population; and (20) repeating steps (16) to (19) until the linear order of nucleotides has been identified for regions of the immobilized target nucleic acid that were hybridized by the target

binding domain of sequencing probes in the second population of sequencing probes. Steps (16) and (17) may occur concurrently or sequentially.

[0013] Each sequencing probe in the second population may de-hybridize from the immobilized target nucleic acid at a different condition (*e.g.*, a higher temperature, higher level of chaotropic agent, higher salt concentration, higher flow rate, and different pH) than the average condition for which the sequencing probes in the first population de-hybridize from the target nucleic acid.

[0014] However, when more than two populations of probes are used, then probes in two sequential populations may de-hybridize at different conditions and probes in non-sequential populations may de-hybridize at similar conditions. As an example, probes in a first population and third population may de-hybridize under similar conditions. In embodiments, sequential populations of probes de-hybridized at increasingly more stringent conditions (*e.g.*, higher levels of chaotropic agent, salt concentration, and temperature). For a microfluidic device, using temperature as an example, a first population of probes may remain hybridized at a first temperature but de-hybridize at a second temperature, which is higher than the first. A second population of probes may remain hybridized at the second temperature but de-hybridize at a third temperature, which is higher than the second. In this example, solutions (comprising reagents required by the present method) flowing over a target nucleic acid for initial probe populations are at a lower temperature than solutions flowing over the target nucleic acid for later probe populations.

[0015] In some embodiments, after a population of probes has been used, the population of probes is de-hybridized from the target nucleic acid and a new aliquot of the same population of probes is used. For example, after a first population of probes has been hybridized, detected, and de-hybridized, a subsequent aliquot of the first population of probes is hybridized. Alternately, as an example, a first population of probes may be de-hybridized and replaced with a second population of probes; once the second population has been detected and de-hybridized, a subsequent aliquot of the first population of probes is hybridized to the target nucleic acid. Thus, a probe in the subsequent population may hybridize to a region of the target nucleic acid that had been previously sequenced (thereby gaining duplicative and/or confirmatory sequence information) or a probe in the subsequent population may hybridize to a region of the target nucleic acid that had not previously been sequenced (thereby gaining new sequence information). Accordingly, a population of probes may be re-aliquoted when a prior read was

unsatisfactory (for any reason) and/or to improve the accuracy of the alignment resulting from the sequencing reads.

[0016] The probes hybridizing and de-hybridizing under similar conditions may have similar lengths of their target binding domain, GC content, or frequency of repeated bases and combinations thereof. Relationships between T_m and length of an oligonucleotide are taught, for example, in Sugimoto *et al.*, *Biochemistry*, 34, 11211-6.

[0017] When more than two populations of probes are used, steps, as described for the first and second populations of sequencing probes, are repeated with additional populations of probes (*e.g.*, 10 to 100 to 1000 populations). The number of populations of probes used will depend on a variety of factors, including but not limited to the size of the target nucleic acid, the number of unique probes in each population, the degree of overlap among sequencing probes desired, and the enrichment of probes to regions of interest.

[0018] A population of probes may contain extra sequencing probes directed to a specific region of interest in a target nucleic acid, *e.g.*, a region containing a mutation (*e.g.*, a point mutation) or a SNP allele. A population of probes may contain fewer sequencing probes directed to a specific region of less interest in a target nucleic acid.

[0019] A population of sequencing probes may be compartmentalized into discrete smaller pools of sequencing probes. The compartmentalization may be based upon predicted melting temperature of the target binding domain in the sequencing probes and/or upon sequence motif of the target binding domain in the sequencing probes. The compartmentalization may be based on empirically-derived rules. The different pools of sequencing probes can be reacted with the target nucleic acid using different reaction conditions, *e.g.*, based on temperature, salt concentration, and/or buffer content. The compartmentalization may be performed to cover target nucleic acid with uniform coverage. The compartmentalization may be performed to cover target nucleic acid with known coverage profile.

[0020] The lengths of target binding domains in a population of sequencing probes may be reduced to increase coverage of probes in a specific region of a target nucleic acid. The lengths of target binding domains in a population of sequencing probes may be increased to decrease coverage of probes in a specific region of a target nucleic acid, *e.g.*, to above the resolution limit of the sequencing apparatus.

[0021] Alternately or additionally, the concentration of sequencing probes in a population may be increased to increase coverage of probes in a specific region of a target nucleic acid. The concentration of sequencing probes may be reduced to decrease coverage of probes in a specific region of a target nucleic acid, *e.g.*, to above the resolution limit of the sequencing apparatus.

[0022] The methods for sequencing a nucleic acid further comprises steps of assembling each identified linear order of nucleotides for each region of the immobilized target nucleic acid, thereby identifying a sequence for the immobilized target nucleic acid. Steps of assembling use a non-transitory computer-readable storage medium with an executable program stored thereon which instructs a microprocessor to arrange each identified linear order of nucleotides, thereby obtaining the sequence of the nucleic acid. Assembling can occur in “real time”, *i.e.*, while data is being collected from sequencing probes rather than after all data has been collected.

[0023] The target nucleic acid, *i.e.*, that is sequenced, may be between about 4 and 1,000,000 nucleotides in length. The target may include a whole, intact chromosome or a fragment thereof either of which is greater than 1,000,000 nucleotides in length.

[0024] Provided herein are apparatuses for performing a method of the present invention.

[0025] Provided herein are kits including sequencing probes of the present invention and for performing methods of the present invention. In embodiments, the kits include a substrate capable of immobilizing a nucleic acid via a capture probe, a plurality of sequencing probes of the present invention, at least one capture probe, at least one complementary nucleic acid molecule having a detectable label, at least one complementary nucleic acid molecule which lacks a detectable label, and instructions for use. In embodiments, the kit comprises about or at least 4096 unique sequencing probes. 4096 is the minimum number of unique probes necessary to include each possible hexameric combination (*i.e.*, for probes each having six attachment regions in the barcode domains). Here, “4096” is achieved since there are four nucleotides options for six positions: 4^6 . For a set of probes having four attachment regions in the barcode domains, only 256 (*i.e.*, 4^4) unique probes will be needed. For a set of probes having eight nucleotides in their target binding domains, 4^8 (*i.e.*, 65,536) unique probes will be needed. For a set of probes having ten nucleotides in their target binding domains, 4^{10} (*i.e.*, 1,048,576) unique probes will be needed.

[0026] In embodiments, the kit comprises about or at least twenty four distinct complementary nucleic acid molecule having a detectable label and about or at least twenty four distinct

hybridizing nucleic acid molecule lacking a detectable label. A complementary nucleic acid may bind to an attachment region having a sequence of one of SEQ ID NO: 1 to 24, as non-limiting examples. Additional exemplary sequences that may be included in a barcode domain are listed in SEQ ID NO: 42 to SEQ ID NO: 81. Indeed, the nucleotide sequence is not limited; preferably it lacks substantial homology (e.g., 50% to 99.9%) with a known nucleotide sequence; this helps avoid undesirable hybridization of a complementary nucleic acid and a target nucleic acid.

[0027] Any of the above aspects and embodiments can be combined with any other aspect or embodiment.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the Specification, the singular forms also include the plural unless the context clearly dictates otherwise; as examples, the terms “a,” “an,” and “the” are understood to be singular or plural and the term “or” is understood to be inclusive. By way of example, “an element” means one or more element. Throughout the specification the word “comprising,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term “about.”

[0029] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present Specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description and claim.

BRIEF DESCRIPTION OF THE DRAWINGS

[0030] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

[0031] The above and further features will be more clearly appreciated from the following detailed description when taken in conjunction with the accompanying drawings.

[0032] Figure 1 to Figure 5 show schematics of exemplary sequencing probes of the present invention.

[0033] Figure 6A to Figure 6D are schematics showing variants of a sequencing probe of the present invention.

[0034] Figure 7 shows schematics of target binding domains of sequencing probes of the present invention; the domains include zero, two, or four nucleotides having universal bases.

[0035] Figure 8A to Figure 8E illustrate steps of a sequencing method of the present invention.

[0036] Figure 9A shows an initial step of a sequencing method of the present invention.

[0037] Figure 9B shows a schematic of a reporter complex comprising detectable labels.

[0038] Figure 9C shows a plurality of reporter complexes each comprising detectable labels.

[0039] Figures 9D to 9G show further steps of the sequencing method begun in Figure 9A.

[0040] Figure 10 shows an alternate illustration of the steps shown in Figure 9D and Figure 9E and exemplary data obtained therefrom. The fragment of the sequencing probe shown has the sequence of SEQ ID NO: 82.

[0041] Figure 11 illustrates a variation of the method shown in Figure 10. The fragment of the sequencing probe shown likewise has the sequence of SEQ ID NO: 82.

[0042] Figure 12 illustrates a method of the present invention.

[0043] Figure 13 compares steps required in a sequencing method of the present invention with steps required with other sequencing methods.

[0044] Figure 14 and Figure 15 exemplify performance measurements obtainable by the present invention.

[0045] Figure 16 compares the sequencing rate, number of reads, and clinical utility for the present invention and various other sequencing methods/apparatuses.

[0046] Figure 17 demonstrates the low raw error rate of sequencing methods of the present invention. The template sequence shown has the sequence of SEQ ID NO: 83.

[0047] Figure 18 compares sequencing data obtainable from the present invention with other sequencing methods.

[0048] Figure 19 demonstrates single-base specificity of sequencing methods of the present invention. The template and probe sequences shown (from top to bottom) have the sequences of SEQ ID NO: 84 to SEQ ID NO: 88.

[0049] Figure 20A shows various designs of reporter complexes of the present invention.

[0050] Figure 20B shows fluorescent counts obtained from the reporter complexes shown in Figure 20A.

[0051] Figure 20C shows exemplary recipes for constructing reporter complexes of the present invention.

[0052] Figure 21A shows designs of reporter complexes comprising “extra-handles”.

[0053] Figure 21B shows fluorescent counts obtained from the reporter complexes having “extra-handles”.

[0054] Figure 22A and Figure 22B show hybridization kinetics of two exemplary designs of reporter complexes of the present invention.

[0055] Figure 23 shows a schematic of a sequencing probe of the present invention used in a method distinct from that shown in Figure 8 through Figure 12.

[0056] Figure 24 shows a schematic of a consumable sequencing card useful in the present invention.

[0057] Figure 25 shows the mismatch detection of a 10 mer, as described in Example 3. The nucleotides shown (top to bottom) have the sequences of SEQ ID NO: 89 to SEQ ID NO: 99.

[0058] Figure 26 shows hybridization ability depending on the size of a target binding domain, as described in Example 3. The background is high due to very high reporter concentration and there was no prior purification. The nucleotides shown (top to bottom) have the sequences of SEQ ID NO: 100 to SEQ ID NO: 104.

[0059] Figure 27 shows a comparison between a single spot vs a full-length reporter. Results for single spots show speed of hybridization is 1000x greater than for a full length barcode (Conditions 100nM target, 30 minute hybridization).

DETAILED DESCRIPTION OF THE INVENTION

[0060] The present invention provides sequencing probes, methods, kits, and apparatuses that provide enzyme-free, amplification-free, and library-free nucleic acid sequencing that has long-read-lengths and with low error rate.

Sequencing Probe

[0061] The present invention relates to a sequencing probe comprising a target binding domain and a barcode domain. Non-limiting examples of sequencing probes of the present invention are shown in Figures 1 to 6.

[0062] Figure 1 shows a schematic of a sequencing probe of the present invention. This exemplary sequencing probe has a target binding domain of six nucleotides, each of which corresponds to a position in the barcode domain (which comprises one or more attachment regions). A first attachment region is noted; it corresponds to the nucleotide of a target nucleic acid bound by a first nucleotide in the target binding domain. The third position on the barcode domain is noted. A fifth position comprising two attachment regions is noted. Each position on a barcode domain can have multiple attachment regions. For example, a position may have 1 to 50 attachment regions. Certain positions in a barcode domain may have more attachment regions than other positions (as shown here in position 5 relative to positions 1 to 4 and 6); alternately, each position in a barcode domain has the same number of attachment regions (see, e.g., Figures 2, 3, 5, and 6). Although not shown, each attachment region comprises at least one (*i.e.*, one to fifty, *e.g.*, ten to thirty) copies of a nucleic acid sequence(s) capable of reversibly binding to a complementary nucleic acid molecule (RNA or DNA). In Figure 1, the attachment regions are integral to the linear polynucleotide molecule that makes up the barcode domain.

[0063] Figure 2 shows a schematic of a sequencing probe of the present invention. This exemplary sequencing probe has a target binding domain of six nucleotides, each of which corresponds to an attachment region in the barcode domain. A first attachment region is noted; it corresponds to the nucleotide of a target nucleic acid bound by a first nucleotide in the target binding domain. The fourth position on the barcode domain, which comprises a portion of the barcode domain and two fourth attachment regions are encircled. Two sixth attachment regions are noted. Here, each position has two attachment regions; however, each position on a barcode domain can have one attachment region or multiple attachment regions, e.g., 2 to 50 attachment

regions. Although not shown, each attachment region comprises at least one (*i.e.*, one to fifty, *e.g.*, ten to thirty) copies of a nucleic acid sequence(s) capable of reversibly binding to a complementary nucleic acid molecule (RNA or DNA). In Figure 2, the barcode domain is a linear polynucleotide molecule to which the attachment regions are linked; the attachment regions are not integral to the polynucleotide molecule.

[0064] Figure 3 shows another a schematic of a sequencing probe of the present invention. This exemplary sequencing probe has a target binding domain of four nucleotides, with these four nucleotides in the corresponding to four positions in the barcode domain. Each position is shown with three linked attachment regions.

[0065] Figure 4 shows yet another schematic of a sequencing probe of the present invention. This exemplary sequencing probe has a target binding domain of ten nucleotides. However, only the first six nucleotides correspond to six positions in the barcode domain. The seventh to tenth nucleotides (indicated by “n₁ to n₄”) are added to increase the length of the target binding domain thereby affecting the likelihood that a probe will hybridize and remain hybridized to a target nucleic acid. In embodiments, “n” nucleotides may precede the nucleotides corresponding to positions in the barcode domain. In embodiments, “n” nucleotides may follow the nucleotides corresponding to positions in the barcode domain. In Figure 4, four “n” nucleotides are shown; however, a target binding domain may include more than four “n” nucleotides. The “n” nucleotides may have universal bases (*e.g.*, inosine, 2'-deoxyinosine (hypoxanthine deoxynucleotide) derivatives, nitroindole, nitroazole analogues, and hydrophobic aromatic non-hydrogen-bonding bases) which can base pair with any of the four canonical bases.

[0066] Another sequencing probe of the present invention is shown in Figure 5. Here, the “n” nucleotides precede and follow the nucleotides corresponding to positions in the barcode domain. The exemplary sequencing probe shown has a target binding domain of ten nucleotides. However, only the third to eighth nucleotides in the target binding domain correspond to six positions (first to sixth) in the barcode domain. The first, second, ninth, and tenth nucleotides (indicated by “n₁ to n₄”) are added to increase the length of the target binding domain. In Figure 5, four “n” nucleotides are shown; however, a target binding domain may include more or less than four “n” nucleotides.

[0067] Figure 6A to Figure 6D show variants of a sequencing probe of Figure 1. In Figure 6A, the linear order of nucleotides in the target binding domain and linear order of attachment

regions in the barcode domain progress from left to right (with respect to the illustration). In Figure 6B, the linear order of nucleotides in the target binding domain and linear order of attachment regions in the barcode domain progress from right to left (with respect to the illustration). In Figure 6C, the linear order of nucleotides in the target binding domain is reversed relative to the linear order of attachment regions in the barcode domain. In any probe of the present invention, there may be a lack of strict order of the nucleotides in the target binding domain and of attachment regions in barcode domain as long as the probe is designed such that each nucleotide in the target binding domain corresponds to an attachment domain or attachment domains in the barcode domain; lacks of strict order is shown in Figure 6D. Any probe of the present invention (e.g., those exemplified in Figures 1 to 5) may have an ordering of nucleotides and attachment regions as shown in Figure 6.

[0068] The target binding domain has at least four nucleotides, *e.g.*, at least, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more nucleotides. The target binding domain preferable is a polynucleotide. The target binding domain is capable of binding a target nucleic acid.

[0069] A probe may include multiple copies of the target binding domain operably linked to a synthetic backbone.

[0070] Probes can be designed to control the likelihood of hybridization and/or de-hybridization and the rates at which these occur. Generally, the lower a probe's T_m , the faster and more likely that the probe will de-hybridize to/from a target nucleic acid. Thus, use of lower T_m probes will decrease the number of probes bound to a target nucleic acid.

[0071] The length of a target binding domain, in part, affects the likelihood of a probe hybridizing and remaining hybridized to a target nucleic acid. Generally, the longer (greater number of nucleotides) a target binding domain is, the less likely that a complementary sequence will be present in the target nucleotide. Conversely, the shorter a target binding domain is, the more likely that a complementary sequence will be present in the target nucleotide. For example, there is a 1/256 chance that a four-mer sequence will be located in a target nucleic acid versus a 1/4096 chance that a six-mer sequence will be located in the target nucleic acid. Consequently, a collection of shorter probes will likely bind in more locations for a given stretch of a nucleic acid when compared to a collection of longer probes.

[0072] Figure 7 shows 10-mer target binding domains. In some embodiments, the target binding domain includes four universal bases (identified as "U_b") which base pair with any of the four

canonical nucleotides (A, G, C, and T). In embodiments, the target binding domain includes one to six (e.g., 2 and 4) universal bases. A target binding domain may include no universal nucleotides. Figure 7 notes that a “complete” population of probes having 6 specific nucleotides in the target binding domain will require 4096 unique probes and a “complete” population of probes having 10 specific nucleotides will require ~1 million unique probes.

[0073] In circumstances, it is preferable to have probes having shorter target binding domains to increase the number of reads in the given stretch of the nucleic acid, thereby enriching coverage of a target nucleic acid or a portion of the target nucleic acid, especially a portion of particular interest, e.g., when detecting a mutation or SNP allele.

[0074] However, it may be preferable to have fewer numbers of probes bound to a target nucleic acid since there are occasions when too many probes in a region may cause overlap of their detectable label, thereby preventing resolution of two nearby probes. This is explained as follows. Given that one nucleotide is 0.34 nm in length and given that the lateral (x-y) spatial resolution of a sequencing apparatus is about 200nm, a sequencing apparatus’s resolution limit is about 588 base pair (*i.e.*, a 1 nucleotide/0.34nm x 200nm). That is to say, the sequencing apparatus mentioned above would be unable to resolve signals from two probes hybridized to a target nucleic acid when the two probes are within about 588 base pair of each other. Thus, two probes, depending on the resolution of the sequencing apparatus, will need be spaced approximately 600bp’s apart before their detectable label can be resolved as distinct “spots”. So, at optimal spacing, there should be a single probe per 600bp of target nucleic-acid. A variety of software approaches (e.g., utilize fluorescence intensity values and wavelength dependent ratios) can be used to monitor, limit, and potentially deconvolve the number of probes hybridizing inside a resolvable region of a target nucleic acid and to design probe populations accordingly. Moreover, detectable labels (e.g., fluorescent labels) can be selected that provide more discrete signals. Furthermore, methods in the literature (e.g., Small and Parthasarthy: “Superresolution localization methods.” *Annu. Rev. Phys. Chem.*, 2014; 65:107-25) describe structured-illumination and a variety of super-resolution approaches which decrease the resolution limit of a sequencing microscope up to 10’s-of-nanometers. Use of higher resolution sequencing apparatuses allow for use of probes with shorter target binding domains.

[0075] As mentioned above, designing the T_m of probes can affect the number of probes hybridized to a target nucleic acid. Alternately or additionally, the concentration of sequencing

probes in a population may be increased to increase coverage of probes in a specific region of a target nucleic acid. The concentration of sequencing probes may be reduced to decrease coverage of probes in a specific region of a target nucleic acid, *e.g.*, to above the resolution limit of the sequencing apparatus.

[0076] The term “target nucleic acid” shall mean a nucleic acid molecule (DNA, RNA, or PNA) whose sequence is to be determined by the probes, methods, and apparatuses of the invention. In general, the terms “target nucleic acid”, “nucleic acid molecule,” “nucleic acid sequence,” “nucleic acid”, “nucleic acid fragment,” “oligonucleotide” and “polynucleotide” are used interchangeably and are intended to include, but not limited to, a polymeric form of nucleotides that may have various lengths, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of nucleic acids include a gene, a gene fragment, an exon, an intron, intergenic DNA (including, without limitation, heterochromatic DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, small interfering RNA (siRNA), non-coding RNA (ncRNA), cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of a sequence, isolated RNA of a sequence, nucleic acid probes, and primers.

[0077] The present methods directly sequence a nucleic acid molecule obtained from a sample, *e.g.*, a sample from an organism, and, preferably, without a conversion (or amplification) step. As an example, for RNA-based sequencing, the present methods do not require conversion of an RNA molecule to a DNA molecule (*i.e.*, via synthesis of cDNA) before a sequence can be obtained. Since no amplification or conversion is required, a nucleic acid sequenced in the present invention will retain any unique base and/or epigenetic marker present in the nucleic acid when the nucleic acid is in the sample or when it was obtained from the sample. Such unique bases and/or epigenetic markers are lost in sequencing methods known in the art.

[0078] The target nucleic acid can be obtained from any sample or source of nucleic acid, *e.g.*, any cell, tissue, or organism, *in vitro*, chemical synthesizer, and so forth. The target nucleic acid can be obtained by any art-recognized method. In embodiments, the nucleic acid is obtained from a blood sample of a clinical subject. The nucleic acid can be extracted, isolated, or purified from the source or samples using methods and kits well known in the art.

[0079] A nucleic acid molecule comprising the target nucleic acid may be fragmented by any means known in the art. Preferably, the fragmenting is performed by an enzymatic or a

mechanical means. The mechanical means may be sonication or physical shearing. The enzymatic means may be performed by digestion with nucleases (*e.g.*, Deoxyribonuclease I (DNase I)) or one or more restriction endonucleases.

[0080] When a nucleic acid molecule comprising the target nucleic acid is an intact chromosome, steps should be taken to avoid fragmenting the chromosome.

[0081] The target nucleic acid can include natural or non-natural nucleotides, comprising modified nucleotides, as well-known in the art.

[0082] Probes of the present invention may have overall lengths (including target binding domain, barcode domain, and any optional domains) of about 20 nanometers to about 50 nanometers. A probe's backbone may be a polynucleotide molecule comprising about 120 nucleotides.

[0083] The barcode domain comprises a synthetic backbone. The synthetic backbone and the target binding domain are operably linked, *e.g.*, are covalently attached or attached via a linker. The synthetic backbone can comprise any material, *e.g.*, polysaccharide, polynucleotide, polymer, plastic, fiber, peptide, peptide nucleic acid, or polypeptide. Preferably, the synthetic backbone is rigid. In embodiments, the backbone comprises "DNA origami" of six DNA double helices (*See, e.g.*, Lin *et al*, "Submicrometre geometrically encoded fluorescent barcodes self-assembled from DNA." *Nature Chemistry*; 2012 Oct; 4(10): 832-9). A barcode can be made of DNA origami tiles (Jungmann *et al*, "Multiplexed 3D cellular super-resolution imaging with DNA-PAINT and Exchange-PAINT", *Nature Methods*, Vol. 11, No. 3, 2014).

[0084] The barcode domain comprises a plurality of positions, *e.g.*, one, two, three, four, five, six, seven, eight, nine, ten, or more positions. The number of positions may be less than, equal to, or more than the number of nucleotides in the target binding domain. It is preferable to include additional nucleotides in a target binding domain than number of positions in the backbone domain, *e.g.*, one, two, three, four, five, six, seven, eight, nine, ten, or more nucleotides. The length of the barcode domain is not limited as long as there is sufficient space for at least four positions, as described above.

[0085] Each position in the barcode domain corresponds to a nucleotide in the target binding domain and, thus, to a nucleotide in the target nucleic acid. As examples, the first position in the barcode domain corresponds to the first nucleotide in the target binding domain and the sixth position in the barcode domain corresponds to the sixth nucleotide in the target binding domain.

[0086] Each position in the barcode domain comprises at least one attachment region, *e.g.*, one to 50, or more, attachment regions. Certain positions in a barcode domain may have more attachment regions than other positions (*e.g.*, a first position may have three attachment regions whereas a second position may have two attachment positions); alternately, each position in a barcode domain has the same number of attachment regions. Each attachment region comprises at least one (*i.e.*, one to fifty, *e.g.*, ten to thirty) copies of a nucleic acid sequence(s) capable of being reversibly bound by a complementary nucleic acid molecule (*e.g.*, DNA or RNA). In examples, the nucleic acid sequence in a first attachment region determines the position and identity of a first nucleotide in the target nucleic acid that is bound by a first nucleotide of the target binding domain. Each attachment region may be linked to a modified monomer (*e.g.*, modified nucleotide) in the synthetic backbone such that the attachment region branches from the synthetic backbone. In embodiments, the attachment regions are integral to a polynucleotide backbone; that is to say, the backbone is a single polynucleotide and the attachment regions are parts of the single polynucleotide's sequence. In embodiments, the terms "barcode domain" and "synthetic backbone" are synonymous.

[0087] The nucleic acid sequence in an attachment region identifies the position and identity of a nucleotide in the target nucleic acid that is bound by a nucleotide in the target binding domain of a sequencing probe. In a probe, each attachment region will have a unique overall sequence. Indeed, each position on a barcode domain can have an attachment region comprising a nucleic acid sequence that encodes one of four nucleotides, *i.e.*, specific to one of adenine, thymine/uracil, cytosine, and guanine. Also, the attachment region of a first position (and encoding cytosine, for example) will include a nucleic acid sequence different from the attachment region of a second position (and encoding cytosine, for example). Thus, to a nucleic acid sequence in an attachment region in a first position that encodes a thymine, there will be no binding of a complementary nucleic acid molecule that identifies an adenine in a target nucleic acid corresponding to the first nucleotide of a target binding domain. Also, to an attachment region in a second position, there will be no binding of a complementary nucleic acid molecule that identifies an adenine in a target nucleic acid corresponding to the first nucleotide of a target binding domain.

[0088] Each position on a barcode domain may include one or more (up to fifty, preferably ten to thirty) attachment region; thus, each attachment region may bind one or more (up to fifty,

preferably ten to thirty) complementary nucleic acid molecules. As examples, the probe in Figure 1 has a fifth position comprising two attachment regions and the probe in Figure 2 has a second position having six attachment regions. In embodiments, the nucleic acid sequences of attachment regions at a position are identical; thus, the complementary nucleic acid molecules that bind those attachment regions are identical. In alternate embodiments, the nucleic acid sequences of attachment regions at a position are not identical; thus, the complementary nucleic acid molecules that bind those attachment regions are not identical, *e.g.*, each comprises a different nucleic acid sequence and/or detectable label. Therefore, in the alternate embodiment, the combination of non-identical nucleic acid molecules (*e.g.*, their detectable labels) attached to an attachment region together provides a code for identifying a nucleotide in the target nucleic acid.

[0089] Table 1 provides exemplary sequences, for illustration purposes only, for attachments regions for sequencing probes having up to six positions in its barcode domain and detectable labels on complementary nucleic acid that bind thereto.

[0090] Table 1:

Nucleotide in target binding domain/position in barcode domain	Nucleotide	Nucleic Acid Sequence (5' to 3') in Attachment Region	Detectable label of complementary nucleic acid	SEQ ID NO
1	A	ATACATCTAG	GFP	1
1	G	GATCTACATA	RFP	2
1	C	TTAGGTAAAG	CFP	3
1	U/T	TCTTCATTAC	YFP	4
2	A	ATGAATCTAC	GFP	5
2	G	TCAATGTATG	RFP	6
2	C	AATTGAGTAC	CFP	7
2	U/T	ATGTTAATGG	YFP	8
3	A	AATTAGGATG	GFP	9
3	G	ATAATGGATC	RFP	10
3	C	TAATAAGGTG	CFP	11
3	U/T	TAGTTAGAGC	YFP	12
4	A	ATAGAGAAGG	GFP	13
4	G	TTGATGATAC	RFP	14
4	C	ATAGTGATTC	CFP	15
4	U/T	TATAACGATG	YFP	16

5	A	TTAAGTTTAG	GFP	17
5	G	ATACGTTATG	RFP	18
5	C	TGTACTATAG	CFP	19
5	U/T	TTAACAAGTG	YFP	20
6	A	AACTATGTAC	GFP	21
6	G	TA ACTATGAC	RFP	22
6	C	ACTAATGTTC	CFP	23
6	U/T	TCATTGAATG	YFP	24

[0091] As seen in Table 1, the nucleic acid sequence of a first attachment region may be one of SEQ ID NO: 1 to SEQ ID NO: 4 and the nucleic acid sequence of a second attachment may be one of SEQ ID NO: 5 to SEQ ID NO: 8. When the first nucleotide in the target nucleic acid is adenine, the nucleic acid sequence of the first attachment region would have the sequence of SEQ ID NO: 1 and when the second nucleotide in the target nucleic acid is adenine, the nucleic acid sequence of the second attachment region would have the sequence of SEQ ID NO: 5.

[0092] In embodiments, a complementary nucleic acid molecule may be bound by a detectable label. In alternate embodiments, a complementary nucleic acid is associated with a reporter complex comprising detectable labels.

[0093] The nucleotide sequence of a complementary nucleic acid is not limited; preferably it lacks substantial homology (e.g., 50% to 99.9%) with a known nucleotide sequence; this helps avoid undesirable hybridization of a complementary nucleic acid and a target nucleic acid.

[0094] An example of the reporter complex useful in the present invention is shown in Figure 9B. In this example, a complementary nucleic acid is linked to a primary nucleic acid molecule, which in turn is hybridized to a plurality of secondary nucleic acid molecules, each of which is in turn hybridized to a plurality of tertiary nucleic acid molecules having attached thereto one or more detectable labels.

[0095] In embodiments, a primary nucleic acid molecule may comprise about 90 nucleotides. A secondary nucleic acid molecule may comprise about 87 nucleotides. A tertiary nucleic acid molecule may comprise about 15 nucleotides.

[0096] Figure 9C shows a population of exemplary reporter complexes. Included in the top left panel of Figure 9C are the four complexes that hybridize to attachment region 1 of a probe. There is one type of reporter complex for each possible nucleotide that can be present in nucleotide position 1 of a probe's target binding domain. Here, while performing a sequence

method of the present invention, if the position 1 of a probe's reporter domain is bound by a reporter complex having a "blue-colored" detectable label, then the first nucleotide in the target binding domain is identified as Adenine. Alternately, if the position 1 is bound by a reporter complex having a "green-colored" detectable label, then the first nucleotide in the target binding domain is identified as Thymine.

[0097] Reporter complexes can be of various designs. For example, a primary nucleic acid molecule can be hybridized to at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) secondary nucleic acid molecules. Each secondary nucleic acid molecule may be hybridized to at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) tertiary nucleic acid molecules. Exemplary reporter complexes are shown in Figure 20A. Here, the "4x3" reporter complex has one primary nucleic acid molecule (that is linked to a complementary nucleic acid molecule) hybridized to four secondary nucleic acid molecules, each of which is hybridized to three tertiary nucleic acid molecules (each comprising a detectable label). In this figure, each complementary nucleic acid of a complex is 12 nucleotides long ("12 bases"); however, the length of the complementary nucleic acid is non-limited and can be less than 12 or more than 12 nucleotides. The bottom-right complex includes a spacer region between its complementary nucleic acid and its primary nucleic acid molecule. The spacer is identified as 20 to 40 nucleotides long; however, the length of a spacer is non-limiting and it can be shorter than 20 nucleotides or longer than 40 nucleotides.

[0098] Figure 20B shows variable average (fluorescent) counts obtained from the four exemplary reporter complexes shown in Figure 20A. In Figure 20B, 10pM of biotinylated target template was attached onto a streptavidin-coated flow-cell surface, 10nM of a reporter complex was flowed onto the flow-cell; after a one minute incubation, the flow-cell was washed, the flow-cell was imaged, and fluorescent features were counted.

[0099] In embodiments, the reporter complexes are "pre-constructed". That is, each polynucleotide in the complex is hybridized prior to contacting the complex with a probe. An exemplary recipe for pre-constructing five exemplary reporter complexes is shown in Figure 20C.

[00100] Figure 21A shows alternate reporter complexes in which the secondary nucleic acid molecules have "extra-handles" that are not hybridized to a tertiary nucleic acid molecule and are distal to the primary nucleic acid molecule. In this figure, each "extra-handle" is 12 nucleotides

long (“12 mer”); however, their lengths are non-limited and can be less than 12 or more than 12 nucleotides. In embodiments, the “extra-handles” each comprise the nucleotide sequence of the complementary nucleic acid; thus, when a reporter complex comprises “extra-handles”, the reporter complex can hybridize to a sequencing probe either via the reporter complex’s complementary nucleic acid or via an “extra-handle.” Accordingly, the likelihood that a reporter complex binds to a sequencing probe is increased. The “extra-handle” design may also improve hybridization kinetics. Without being bound to theory, the “extra-handles” essentially increase the effective concentration of the reporter complex’s complementary nucleic acid.

[00101] Figure 21B shows variable average (fluorescent) counts obtained from the five exemplary reporter complexes having “extra-handles” using the procedure described for Figure 20B.

[00102] Figure 22A and 22B show hybridization kinetics and fluorescent intensities for two exemplary reporter complexes. By about 5 minutes, total counts start to plateau indicating that most reporter complex added have found an available target.

[00103] A detectable moiety, label or reporter can be bound to a complementary nucleic acid or to a tertiary nucleic acid molecule in a variety of ways, including the direct or indirect attachment of a detectable moiety such as a fluorescent moiety, colorimetric moiety and the like. One of skill in the art can consult references directed to labeling nucleic acids. Examples of fluorescent moieties include, but are not limited to, yellow fluorescent protein (YFP), green fluorescent protein (GFP), cyan fluorescent protein (CFP), red fluorescent protein (RFP), umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, cyanines, dansyl chloride, phycocyanin, phycoerythrin and the like. Fluorescent labels and their attachment to nucleotides and/or oligonucleotides are described in many reviews, including Haugland, Handbook of Fluorescent Probes and Research Chemicals, Ninth Edition (Molecular Probes, Inc., Eugene, 2002); Keller and Manak, DNA Probes, 2nd Edition (Stockton Press, New York, 1993); Eckstein, editor, Oligonucleotides and Analogues: A Practical Approach (IRL Press, Oxford, 1991); and Wetmur, Critical Reviews in Biochemistry and Molecular Biology, 26:227-259 (1991). Particular methodologies applicable to the invention are disclosed in the following sample of references: U.S. Patent Nos. 4,757,141; 5,151,507; and 5,091,519. In one aspect, one or more fluorescent dyes are used as labels for labeled target sequences, *e.g.*, as disclosed by U.S. Patent Nos. 5,188,934 (4,7-dichlorofluorescein dyes); 5,366,860 (spectrally resolvable rhodamine dyes); 5,847,162 (4,7-dichlororhodamine dyes); 4,318,846 (ether-

substituted fluorescein dyes); 5,800,996 (energy transfer dyes); Lee *et al.* 5,066,580 (xanthine dyes); 5,688,648 (energy transfer dyes); and the like. Labelling can also be carried out with quantum dots, as disclosed in the following patents and patent publications: U.S. Patent Nos. 6,322,901; 6,576,291; 6,423,551; 6,251,303; 6,319,426; 6,426,513; 6,444,143; 5,990,479; 6,207,392; 2002/0045045; and 2003/0017264. As used herein, the term “fluorescent label” comprises a signaling moiety that conveys information through the fluorescent absorption and/or emission properties of one or more molecules. Such fluorescent properties include fluorescence intensity, fluorescence lifetime, emission spectrum characteristics, energy transfer, and the like.

[00104] Commercially available fluorescent nucleotide analogues readily incorporated into nucleotide and/or oligonucleotide sequences include, but are not limited to, Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy5-dUTP (Amersham Biosciences, Piscataway, NJ), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, TEXAS RED™-5-dUTP, CASCADE BLUE™-7-dUTP, BODIPY TMFL-14-dUTP, BODIPY TMR-14-dUTP, BODIPY TMTR-14-dUTP, RHODAMINE GREEN™-5-dUTP, OREGON GREENR™ 488-5-dUTP, TEXAS RED™-12-dUTP, BODIPY TM 630/650-14-dUTP, BODIPY TM 650/665-14-dUTP, ALEXA FLUOR™ 488-5-dUTP, ALEXA FLUOR™ 532-5-dUTP, ALEXA FLUOR™ 568-5-dUTP, ALEXA FLUOR™ 594-5-dUTP, ALEXA FLUOR™ 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, TEXAS RED™-5-UTP, mCherry, CASCADE BLUE™-7-UTP, BODIPY TM FL-14-UTP, BODIPY TMR-14-UTP, BODIPY TM TR-14-UTP, RHODAMINE GREEN™-5-UTP, ALEXA FLUOR™ 488-5-UTP, ALEXA FLUOR™ 546-14-UTP (Molecular Probes, Inc. Eugene, OR) and the like. Alternatively, the above fluorophores and those mentioned herein may be added during oligonucleotide synthesis using for example phosphoramidite or NHS chemistry. Protocols are known in the art for custom synthesis of nucleotides having other fluorophores (*See*, Henegariu *et al.* (2000) *Nature Biotechnol.* 18:345). 2-Aminopurine is a fluorescent base that can be incorporated directly in the oligonucleotide sequence during its synthesis. Nucleic acid could also be stained, *a priori*, with an intercalating dye such as DAPI, YOYO-1, ethidium bromide, cyanine dyes (*e.g.*, SYBR Green) and the like.

[00105] Other fluorophores available for post-synthetic attachment include, but are not limited to, ALEXA FLUOR™ 350, ALEXA FLUOR™ 405, ALEXA FLUOR™ 430, ALEXA FLUOR™ 532, ALEXA FLUOR™ 546, ALEXA FLUOR™ 568, ALEXA FLUOR™ 594, ALEXA FLUOR™ 647, BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY

TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, Pacific Orange, rhodamine 6G, rhodamine green, rhodamine red, tetramethyl rhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7 (Amersham Biosciences, Piscataway, NJ) and the like. FRET tandem fluorophores may also be used, including, but not limited to, PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, APC-Cy7, PE-Alexa dyes (610, 647, 680), APC-Alexa dyes and the like.

[00106] Metallic silver or gold particles may be used to enhance signal from fluorescently labeled nucleotide and/or oligonucleotide sequences (Lakowicz *et al.* (2003) *BioTechniques* 34:62).

[00107] Other suitable labels for an oligonucleotide sequence may include fluorescein (FAM, FITC), digoxigenin, dinitrophenol (DNP), dansyl, biotin, bromodeoxyuridine (BrdU), hexahistidine (6xHis), phosphor-amino acids (*e.g.*, P-tyr, P-ser, P-thr) and the like. In one embodiment the following hapten/antibody pairs are used for detection, in which each of the antibodies is derivatized with a detectable label: biotin/a-biotin, digoxigenin/a-digoxigenin, dinitrophenol (DNP)/a-DNP, 5-Carboxyfluorescein (FAM)/a-FAM.

[00108] Detectable labels described herein are spectrally resolvable. "Spectrally resolvable" in reference to a plurality of fluorescent labels means that the fluorescent emission bands of the labels are sufficiently distinct, *i.e.*, sufficiently non-overlapping, that molecular tags to which the respective labels are attached can be distinguished on the basis of the fluorescent signal generated by the respective labels by standard photodetection systems, *e.g.*, employing a system of band pass filters and photomultiplier tubes, or the like, as exemplified by the systems described in U.S. Patent Nos. 4,230,558; 4,811,218; or the like, or in Wheelless *et al.*, pgs. 21-76, in *Flow Cytometry: Instrumentation and Data Analysis* (Academic Press, New York, 1985). In one aspect, spectrally resolvable organic dyes, such as fluorescein, rhodamine, and the like, means that wavelength emission maxima are spaced at least 20 nm apart, and in another aspect, at least 40 nm apart. In another aspect, chelated lanthanide compounds, quantum dots, and the like, spectrally resolvable means that wavelength emission maxima are spaced at least 10 nm apart, and in a further aspect, at least 15 nm apart.

Sequencing Method

[00109] The present invention relates to methods for sequencing a nucleic acid using a sequencing probe of the present invention. Examples of the method are shown in Figures 8 to 12.

[00110] The method comprises reversibly hybridizing at least one sequencing probe, of the present invention, to a target nucleic acid that is immobilized (*e.g.*, at one, two, three, four, five, six, seven, eight, nine, ten, or more positions) to a substrate.

[00111] The substrate can be any solid support known in the art, *e.g.*, a coated slide and a microfluidic device, which is capable of immobilizing a target nucleic acid. In certain embodiments, the substrate is a surface, membrane, bead, porous material, electrode or array. The target nucleic acid can be immobilized onto any substrate apparent to those of skill in the art.

[00112] In embodiments, the target nucleic acid is bound by a capture probe which comprises a domain that is complementary to a portion of the target nucleic acid. The portion may be an end of the target nucleic acid or not towards an end.

[00113] Exemplary useful substrates include those that comprise a binding moiety selected from the group consisting of ligands, antigens, carbohydrates, nucleic acids, receptors, lectins, and antibodies. The capture probe comprises a binding moiety capable of binding with the binding moiety of the substrate. Exemplary useful substrates comprising reactive moieties include, but are not limited to, surfaces comprising epoxy, aldehyde, gold, hydrazide, sulfhydryl, NHS-ester, amine, thiol, carboxylate, maleimide, hydroxymethyl phosphine, imidoester, isocyanate, hydroxyl, pentafluorophenyl-ester, psoralen, pyridyl disulfide or vinyl sulfone, polyethylene glycol (PEG), hydrogel, or mixtures thereof. Such surfaces can be obtained from commercial sources or prepared according to standard techniques. Exemplary useful substrates comprising reactive moieties include, but are not limited to, OptArray-DNA NHS group (Accelr8), Nexterion Slide AL (Schott) and Nexterion Slide E (Schott).

[00114] In embodiments, the capture probe's binding moiety is biotin and the substrate comprises avidin (*e.g.*, streptavidin). Useful substrates comprising avidin are commercially available including TB0200 (Accelr8), SAD6, SAD20, SAD100, SAD500, SAD2000 (Xantec), SuperAvidin (Array-It), streptavidin slide (catalog #MPC 000, Xenopore) and STREPTAVIDINnslide (catalog #439003, Greiner Bio-one).

[00115] In embodiments, the capture probe's binding moiety is avidin (*e.g.*, streptavidin) and the substrate comprises biotin. Useful substrates comprising biotin that are commercially available include, but are not limited to, Optiarray-biotin (Accler8), BD6, BD20, BD100, BD500 and BD2000 (Xantec).

[00116] In embodiments, the capture probe's binding moiety can comprise a reactive moiety that is capable of being bound to the substrate by photoactivation. The substrate could comprise the photoreactive moiety, or the first portion of the nanoreporter could comprise the photoreactive moiety. Some examples of photoreactive moieties include aryl azides, such as N((2-pyridyldithio)ethyl)-4-azidosalicylamide; fluorinated aryl azides, such as 4-azido-2,3,5,6-tetrafluorobenzoic acid; benzophenone-based reagents, such as the succinimidyl ester of 4-benzoylbenzoic acid; and 5-Bromo-deoxyuridine.

[00117] In embodiments, the capture probe's binding moiety can be immobilized to the substrate via other binding pairs apparent to those of skill in the art.

[00118] After binding to the substrate, the target nucleic acid may be elongated by applying a force (*e.g.*, gravity, hydrodynamic force, electromagnetic force "electrostretching", flow-stretching, a receding meniscus technique, and combinations thereof) sufficient to extend the target nucleic acid.

[00119] The target nucleic acid may be bound by a second capture probe which comprises a domain that is complementary to a second portion of the target nucleic acid. The portion may be an end of the target nucleic acid or not towards an end. Binding of a second capture probe can occur after or during elongation of the target nucleic acid or to a target nucleic acid that has not been elongated. The second capture probe can have a binding as described above.

[00120] A capture probe may comprise or be associated with a detectable label, *i.e.*, a fiducial spot.

[00121] The capture probe is capable of isolating a target nucleic acid from a sample. Here, a capture probe is added to a sample comprising the target nucleic acid. The capture probe binds the target nucleic acid via the region of the capture probe that is complementary to a region of the target nucleic acid. When the target nucleic acid contacts a substrate comprising a moiety that binds the capture probe's binding moiety, the nucleic acid becomes immobilized onto the substrate.

[00122] To ensure that a user “captures” as many target nucleic acid molecules as possible from high fragmented samples, it is helpful to include a plurality of capture probes, each complementary to a different region of the target nucleic acid. For example, there may be three pools of capture probes, with a first pool complementary to regions of the target nucleic acid near its 5' end, a second pool complementary to regions in the middle of the target nucleic acid, and a third pool near its 3' end. This can be generalized to “n-regions-of-interest” per target nucleic acid. In this example, each individual pool of fragmented target nucleic acid bound to a capture probe comprising or bound to a biotin tag. $1/n$ th of input sample (where n = the number of distinct regions in target nucleic acid) is isolated for each pool chamber. The capture probe binds the target nucleic acid of interest. Then the target nucleic acid is immobilized, via the capture probe's biotin, to an avidin molecule adhered to the substrate. Optionally, the target nucleic acid is stretched, *e.g.*, via flow or electrostatic force. All n -pools can be stretched-and-bound simultaneously, or, in order to maximize the number of fully stretched molecules, pool 1 (which captures most 5' region) can be stretched and bound first; then pool 2, (which captures the middle-of-target region) is then can be stretched and bound; finally, pool 3 is can be stretched and bound.

[00123] The number of distinct capture probes required is inversely related to the size of target nucleic acid fragment. In other word, more capture probes will be required for a highly-fragmented target nucleic acid. For sample types with highly fragmented and degraded target nucleic acids (*e.g.*, Formalin-Fixed Paraffin Embedded Tissue) it may be useful to include multiple pools of capture probes. On the other hand, for samples with long target nucleic acid fragments, *e.g.*, in vitro obtained isolated nucleic acids, a single capture probe at a 5' end may be sufficient.

[00124] The region of the target nucleic acid between to two capture probes or after one capture probe and before a terminus of the target nucleic acid is referred herein as a “gap”. The gap is a portion of the target nucleic acid that is available to be bound by a sequencing probe of the present invention. The minimum gap is a target binding domain length (*e.g.*, 4 to 10 nucleotides) and a maximum gap is the majority of a whole chromosome.

[00125] An immobilized target nucleic acid is shown in Figure 12. Here, the two capture probes are identified as “5' capture probe” and “3' capture probe”. .

[00126] Figure 8A shows a schematic of a sequencing probe bound to a target nucleic acid. Here, the target nucleic acid has a thymidine (T). A first pool of complementary nucleic acids comprising a detectable label or reporter complexes is shown at the top, each member of the pool has a different detectable label (*e.g.*, thymidine is identified by a green signal) and a different nucleotide sequence. The first nucleotide in the target binding domain binds the T in the target nucleic acid. The first attachment regions of the probe include one or more nucleotide sequence(s) that specifies that the first nucleotide in the probe's target binding domain binds a thymidine. Thus, only the complementary nucleic acid for thymidine binds the first position of the barcode domain. As shown, a thymidine-encoding first complementary nucleic acid comprising a detectable label or reported complexes comprising detectable labels are bound to attachment regions in the first position of the probe's barcode domain.

[00127] The number of pools of complementary nucleic acids or reporter complexes is identical to the number of positions in the barcode domain. Thus, for a barcode domain having six positions, six pools will be cycled over the probes.

[00128] Alternately, prior to contacting a target nucleic acid with a probe, the probe may be hybridized at its first position to a complementary nucleic acid comprising a detectable label or a reporter complex. Thus, when contacted with its target nucleic acid, the probe is capable of emitting a detectable signal from its first position and it is unnecessary to provide a first pool of complementary nucleic acids or reporter complexes that are directed to the first position on the barcode domain.

[00129] Figure 8B continues the method shown in Figure 8A. Here, the first complementary nucleic acids (or reporter complexes) for thymidine that were bound to attachment regions in the first position of the barcode domain have been replaced with a first hybridizing nucleic acid for thymidine and lacking a detectable label. The first hybridizing nucleic acid for thymidine and lacking a detectable label displaces the previously-bound complementary nucleic acids comprising a detectable label or the previously-bound reporter complexes. Thereby, position 1 of the barcode domain no longer emits a detectable signal.

[00130] In embodiments, the complementary nucleic acids comprising a detectable label or reporter complexes may be removed from the attachment region but not replaced with a hybridizing nucleic acid lacking a detectable label. This can occur, for example, by adding a chaotropic agent, increasing the temperature, changing salt concentration, adjusting pH, and/or

applying a hydrodynamic force. In these embodiments fewer reagents (*i.e.*, hybridizing nucleic acids lacking detectable labels) are needed.

[00131] Figure 8C continues the method of the claimed invention. Here, the target nucleic acid has a cytidine (C) following its thymidine (T). A second pool of complementary nucleic acids or reporter complexes is shown at the top, each member of the pool has a different detectable label and a different nucleotide sequence. Moreover, the nucleotide sequences for the complementary nucleic acids or complementary nucleic acids of the reporter complexes of the first pool are different from the nucleotide sequences for those of the second pool. However, the base specific detectable labels are common to the pools of complementary nucleic acids, *e.g.*, thymidines are identified by green signals. Here, the second nucleotide in the target binding domain binds the C in the target nucleic acid. The second attachment regions of the probe have a nucleotide sequence that specifies that the second nucleotide in the probe's target binding domain binds a cytidine. Thus, only the complementary nucleic acids comprising a detectable label or reporter complexes from the second pool and for cytidine binds the second position of the barcode domain. As shown, the cytidine-encoding second complementary nucleic acid or reporter complex is bound at the second position of the probe's barcode domain.

[00132] In embodiments, the steps shown in Figure 8C are subsequent to steps shown in Figure 8B. Here, once the first pool of complementary nucleic acids or reporter complexes (of Figure 8A) has been replaced with first hybridizing nucleic acids lacking a detectable label (in Figure 8B), then a second pool of complementary nucleic acids or reporter complexes is provided (as shown in Figure 8C). Alternately, the steps shown in Figure 8C are concurrent with steps shown in Figure 8B. Here, the first hybridizing nucleic acids lacking a detectable label (in Figure 8B) are provided simultaneously with a second pool of complementary nucleic acids or reporter complexes (as shown in Figure 8C).

[00133] Figure 8D continues the method shown in Figure 8C. Here, the first through fifth positions on the barcode domain were bound by complementary nucleic acids comprising a detectable labels or reporter complexes and have been replaced with hybridizing nucleic acids lacking detectable labels. The sixth position of the barcode domain is currently bound by a complementary nucleic acid comprising a detectable label or reporter complex, which identifies the sixth position in the target binding domain as being bound to a guanine (G).

[00134] As mentioned above, complementary nucleic acids comprising detectable labels or reporter complexes can be removed from attachment regions but not replaced with hybridizing nucleic acid lacking detectable labels.

[00135] If needed, the rate of detectable label exchange can be accelerated by incorporating small single-stranded oligonucleotides that accelerate the rate of exchange of detectable labels (*e.g.*, “Toe-Hold” Probes; *see, e.g.*, Seeling *et al.*, “Catalyzed Relaxation of a Metastable DNA Fuel”; *J. Am. Chem. Soc.* 2006, 128(37), pp12211-12220).

[00136] It is possible to replace the complementary nucleic acids or reporter complexes on a final position on a barcode domain (the sixth position in Figure 8D); however, this may be unnecessary when a sequencing probe is to be replaced with another sequencing probe. Indeed, the sequencing probe of Figure 8D can now be de-hybridized and removed from the target nucleic acid and replaced with a second (overlapping or non-overlapping) sequencing probe that has not yet been bound by any complementary nucleic acids, as shown in Figure 8E. The probe in Figure 8E may be included in a second population of probes.

[00137] Like Figures 8A to 8E, Figures 9A and 9D to 9G show method steps of the present invention; however, Figures 9A and 9D to 9G clearly show that reporter complexes (comprising detectable labels) are bound to attachment regions of sequencing probes. Figures 9D and 9E show fluorescent signals emitted from probes hybridized to reporter complexes. Figures 9D and 9E show that the target nucleic acid has a sequence of “T-A”.

[00138] Figure 10 summarizes the steps shown in Figures 9D and 9E. At the top of the figure is shown the nucleotide sequence of an exemplary probe and identifies significant domains of the probe. The probe includes an optional double-stranded DNA spacer between its target binding domain and its barcode domain. The barcode domain comprises, in order, a “Flank 1” portion, an “AR-1” portion, an “AR-1/Flank 2” portion, an “AR-2” portion, and an “AR-2/Flank 3” portion. In Step 1, the “AR-1 Detect” is hybridized to the probe’s “AR-1” and “AR-1/Flank 2” portions. “AR-1 Detect” corresponds to a reporter complex or complementary nucleic acid comprising a detectable label that encodes a first position thymidine. Thus, Step 1 corresponds to Figure 9D. In Step 2, the “Lack 1” is hybridized to the probe’s “Flank 1” and “AR-1” portions. “Lack 1” corresponds to the hybridizing nucleic acid lacking a detectable label that is specific to the probe’s first attachment region (as shown in Figure 9E as a black bar covering the first attachment region). By hybridizing to the “Flank 1” position, which is 5’ to the reporter complex

or complementary nucleic acid, the hybridizing nucleic acid more efficiently displaces the reporter complex/complementary nucleic acid from the probe. The “Flank” portions are also known as “Toe-Holds”. In Step 3, the “AR-2 Detect” is hybridized to the probe’s “AR-2” and “AR-2/Flank 3” portions. “AR-2 Detect” corresponds to a reporter complex or complementary nucleic acid comprising a detectable label that encodes a second position Guanine. Thus, Step 3 corresponds to Figure 9E. In this embodiment, hybridizing nucleic acid lacking a detectable label and complementary nucleic acids comprising detectable labels/reporter complexes are provided sequentially.

[00139] Alternately, hybridizing nucleic acid lacking a detectable label and complementary nucleic acids comprising detectable labels/reporter complexes are provided concurrently. This alternate embodiment is shown in Figure 11. In Step 2, the “Lack 1” (hybridizing nucleic acid lacking a detectable label) is provided along with the “AR-2 Detect” (reporter complex that encodes a second position Guanine). This alternate embodiment may be more time effective than the embodiment illustrated in Figure 10 because it combines two steps into one.

[00140] Figure 12 illustrates the methods of the present invention. Here, a target nucleic acid is captured and immobilized at two positions, thereby producing a “gap” to which a probe is able to bind. A first population of probes is hybridized onto the target nucleic acid and detectable labels are detected. The initial steps are repeated with a second population of probes, a third population of probes, to more than 100 populations of probes. Use of about 100 populations of probes provides about 5X coverage of each nucleotide in a target nucleic acid. Figure 12 provides estimated rates of read times based on the time required to detect signals from one Field of View (FOV).

[00141] The distribution of probes along a length of target nucleic acid is critical for resolution of detectable signal. As discussed above, the resolution limit for two detectable labels is about 600 nucleotides. Preferably, each sequencing probe in a population of probes will bind no closer than 600 nucleotides from each other. As discussed above, 600 nucleotides is the resolution limit of a typical sequencing apparatus. In this case, a sequencing probe will provide a single read; this is shown in Figure 12 in the left-most resolution-limited spot.

[00142] Randomly, but in part depending on the length of the target binding domain, the T_m of the probes, and concentration of probes applied, it is possible for two distinct sequencing probes in a population to bind within 600 nucleotides of each other. In this case, unordered multiple

reads will emit from a single resolution-limited spot; this is shown in Figure 12 in the second resolution-limited spot.

[00143] Alternately or additionally, the concentration of sequencing probes in a population may be reduced to decrease coverage of probes in a specific region of a target nucleic acid, *e.g.*, to above the resolution limit of the sequencing apparatus, thereby producing a single read from a resolution-limited spot.

[00144] Figure 23 shows a schematic of a sequencing probe distinct from that used in Figures 8 through 12. Here, each position on a barcode domain is bound by complementary nucleic acids comprising detectable labels or by reporter complexes. Thus, in this example, a six nucleotide sequence can be read without needing to sequentially replace complementary nucleic acids. Use of this sequencing probe would reduce the time to obtain sequence information since many steps of the described method are omitted. However, this probe would benefit from detectable labels that are non-overlapping, *e.g.*, fluorophores are excited by non-overlapping wavelengths of light or the fluorophores emit non-overlapping wavelengths of light.

[00145] The method further comprising steps of assembling each identified linear order of nucleotides for each region of the immobilized target nucleic acid, thereby identifying a sequence for the immobilized target nucleic acid. The steps of assembling uses a non-transitory computer-readable storage medium with an executable program stored thereon. The program instructs a microprocessor to arrange each identified linear order of nucleotides for each region of the target nucleic acid, thereby obtaining the sequence of the nucleic acid. Assembling can occur in “real time”, *i.e.*, while data is being collected from sequencing probes rather than after all data has been collected.

[00146] Any of the above aspects and embodiments can be combined with any other aspect or embodiment as disclosed here in the Summary and/or Detailed Description sections.

Definitions:

[00147] In certain exemplary embodiments, the terms “annealing” and “hybridization,” as used herein, are used interchangeably to mean the formation of a stable duplex. In one aspect, stable duplex means that a duplex structure is not destroyed by a stringent wash under conditions such as a temperature of either about 5 °C below or about 5 °C above the T_m of a strand of the duplex

and low monovalent salt concentration, *e.g.*, less than 0.2 M, or less than 0.1 M or salt concentrations known to those of skill in the art. The term “perfectly matched,” when used in reference to a duplex means that the polynucleotide and/or oligonucleotide strands making up the duplex form a double stranded structure with one another such that every nucleotide in each strand undergoes Watson-Crick base pairing with a nucleotide in the other strand. The term “duplex” comprises, but is not limited to, the pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine bases, PNAs, and the like, that may be employed. A “mismatch” in a duplex between two oligonucleotides means that a pair of nucleotides in the duplex fails to undergo Watson-Crick bonding.

[00148] As used herein, the term “hybridization conditions,” will typically include salt concentrations of less than about 1 M, more usually less than about 500 mM and even more usually less than about 200 mM. Hybridization temperatures can be as low as 5 °C, but are typically greater than 22 °C, more typically greater than about 30 °C, and often in excess of about 37 °C. Hybridizations are usually performed under stringent conditions, *e.g.*, conditions under which a probe will specifically hybridize to its target subsequence. Stringent conditions are sequence-dependent and are different in different circumstances. Longer fragments may require higher hybridization temperatures for specific hybridization. As other factors may affect the stringency of hybridization, including base composition and length of the complementary strands, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one alone.

[00149] Generally, stringent conditions are selected to be about 5 °C lower than the T_m for the specific sequence at a defined ionic strength and pH. Exemplary stringent conditions include salt concentration of at least 0.01 M to no more than 1 M Na ion concentration (or other salts) at a pH 7.0 to 8.3 and a temperature of at least 25 °C. For example, conditions of 5X SSPE (750 mM NaCl, 50 mM Na phosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30 °C are suitable for allele-specific probe hybridizations. For stringent conditions, see for example, Sambrook, Fritsche and Maniatis, “Molecular Cloning A Laboratory Manual, 2nd Ed.” Cold Spring Harbor Press (1989) and Anderson Nucleic Acid Hybridization, 1st Ed., BIOS Scientific Publishers Limited (1999). As used herein, the terms “hybridizing specifically to” or “specifically hybridizing to” or similar terms refer to the binding, duplexing, or hybridizing of a molecule substantially to a particular nucleotide sequence or sequences under stringent conditions.

[00150] Detectable labels associated with a particular position of a probe can be “readout” (e.g., its fluorescence detected) once or multiple times; a “readout” may be synonymous with the term “basecall”. Multiple reads improve accuracy. A target nucleic acid sequence is “read” when a contiguous stretch of sequence information derived from a single original target molecule is detected; typically, this is generated via multi-pass consensus (as defined below). As used herein, the term “coverage” or “depth of coverage” refers to the number of times a region of target has been sequenced (via discrete reads) and aligned to a reference sequence. Read coverage is the total number of reads that map to a specific reference target sequence; base coverage is the total number of basecalls made at a specific genomic position.

[00151] As used in herein, a “hybe and seq cycle” refers to all steps required to detect each attachment region on a particular probe or population of probes. For example, for a probe capable of detecting six positions on a target nucleic acid, one “hybe and seq cycle” will include, at least, hybridizing the probe to the target nucleic acid, hybridizing complementary nucleic acids/reporter complexes to attachment region at each of the six positions on the probe’s barcode domain, and detecting the detectable labels associated with each of the six positions.

[00152] The term “k-mer probe” is synonymous with a probe of the present invention.

[00153] When two or more sequences from discrete reads are aligned, the overlapping portions can be combined to create a single consensus sequence. In positions where overlapping portions have the same base (a single column of the alignment), those bases become the consensus. Various rules may be used to generate the consensus for positions where there are disagreements among overlapping sequences. A simple majority rule uses the most common base in the column as the consensus. A “multi-pass consensus” is an alignment of all discrete probe readouts from a single target molecule. Depending on the total number of cycles of probe populations/polls applied, each base position within a single target molecules can be queried with different levels of redundancy or overlap; generally, redundancy increases the confidence level of a basecall.

[00154] The “Raw Accuracy” is a measure of system’s inherent ability to correctly identify a base. Raw accuracy is dependent on sequencing technology. “Consensus Accuracy” is a measure of system’s ability to correctly identify a base with the use of additional reads and statistical power. “Specificity” refers to the percentage of reads that map to the intended targets out of total reads per run. “Uniformity” refers to the variability in sequence coverage across target regions; high uniformity correlates with low variability. This feature is commonly

reported as the fraction of targeted regions covered by $\geq 20\%$ of the average coverage depth across all targeted regions. Stochastic errors (i.e., intrinsic sequencing chemistry errors) can be readily corrected with 'multi-pass' sequencing of same target nucleic acid; given a sufficient number of passes, substantially 'perfect consensus' or 'error-free' sequencing can be achieved.

The methods described herein may be implemented and/or the results recorded using any device capable of implementing the methods and/or recording the results. Examples of devices that may be used include but are not limited to electronic computational devices, including computers of all types. When the methods described herein are implemented and/or recorded in a computer, the computer program that may be used to configure the computer to carry out the steps of the methods may be contained in any computer readable medium capable of containing the computer program. Examples of computer readable medium that may be used include but are not limited to diskettes, CD-ROMs, DVDs, ROM, RAM, non-transitory computer-readable media, and other memory and computer storage devices. The computer program that may be used to configure the computer to carry out the steps of the methods, assemble sequence information, and/or record the results may also be provided over an electronic network, for example, over the internet, an intranet, or other network.

[00155] A "Consumable Sequencing Card" (Figure 24) can be incorporated into a fluorescence imaging device known in the art. Any fluorescence microscope with a number of varying features is capable of performing this sequencing readout. For instance: wide-field lamp, laser, LED, multi-photon, confocal or total-internal reflection illumination can be used for excitation and/or detection. Camera (single or multiple) and/or Photomultiplier tube (single or multiple) with either filter-based or grating-based spectral resolution (one or more spectrally resolved emission wavelengths) are possible on the emission-detection channel of the fluorescence microscope. Standard computers can control both the Consumable Sequencing Card, the reagents flowing through the Card, and detection by the fluorescence microscope.

[00156] The sequencing data can be analyzed by any number of standard next-generation-sequencing assemblers (*see, e.g.*, Wajid and Serpedin, "Review of general algorithmic features for genome assemblers for next generation sequencers" *Genomics, proteomics & bioinformatics*, 10 (2), 58-73, 2012). The sequencing data obtained within a single diffraction limited region of the microscope is "locally-assembled" to generate a consensus sequence from the multiple reads within a diffraction spot. The multiple diffraction spot assembled reads are then mapped

together to generate contiguous sequences representing the entire targeted gene set, or a de-novo assembly of entire genome(s).

[00157] Additional teaching relevant to the present invention are described in one or more of the following: U.S. 8,148,512, U.S. 7,473,767, U.S. 7,919,237, U.S. 7,941,279, U.S. 8,415,102, U.S. 8,492,094, U.S. 8,519,115, U.S. 2009/0220978, U.S. 2009/0299640, U.S. 2010/0015607, U.S. 2010/0261026, U.S. 2011/0086774, U.S. 2011/0145176, U.S. 2011/0201515, U.S. 2011/0229888, U.S. 2013/0004482, U.S. 2013/0017971, U.S. 2013/0178372, U.S. 2013/0230851, U.S. 2013/0337444, U.S. 2013/0345161, U.S. 2014/0005067, U.S. 2014/0017688, U.S. 2014/0037620, U.S. 2014/0087959, U.S. 2014/0154681, and U.S. 2014/0162251, each of which is incorporated herein by reference in their entireties.

EXAMPLES

Example 1: The present invention's method of sequencing a target nucleic acid is rapid

[00158] Below is described the timing for steps in the methods of the present invention and as shown in Figures 8 to 12.

[00159] The present invention requires minimal sample preparation. For example, as shown in Figure 13, nucleic acids in a sample can begin to be read after 2 hours or less of preparation time; this is significantly less time required for Ion Torrent (AmpliSeq™) or Illumina (TruSight) sequencing, which, respectively, require about 12 or 9 hours of preparation time.

[00160] Calculations for an exemplary run are shown in Figure 14 and calculations for cycling times are shown in Figure 15.

[00161] Binding a population of probes to an immobilized target nucleic acid takes about sixty seconds. This reaction can be accelerated by utilizing multiple copies of the target binding domain on the synthetic backbone. With microfluidic-controlled fluid exchange device, washing away un-bound probes takes about a half a second.

[00162] Adding a first pool of complementary nucleic acids (comprising a detectable label) and binding them to attachment regions in the first position of the barcode domain takes about fifteen seconds.

[00163] Each field of view (FOV) is imaged for four different colors, each color representing a single-base. Fiducial spots placed on a 5' capture probe or 3' capture probe (or both) may be

helpful for reading only those optical barcodes in-a-line (consistent with the presence of gapped target nucleic acid) between the two locations. Fiducial spots can also be added to each field of view in order to generate equal alignment of images upon successive steps in the sequencing process. All four images can be obtained at a single FOV and then the optical reading device may move to a new FOV, or take all FOV in one color then reimage in a second color. A single FOV can be read in about a half a second. It takes about a half a second to move to a next FOV. Therefore, the time to read “n” FOV’s equals “n” times 1 sec).

[00164] The complementary nucleic acids having detectable labels are removed from the first position of the barcode domain by addition of heat or washing with excess of complementary nucleic acids lacking detectable labels. If needed, the rate of detectable label exchange can be accelerated by incorporating small single-stranded oligonucleotides that accelerate the rate of exchange of detectable labels (*e.g.*, “Toe-Hold” Probes; *see, e.g.*, Seeling *et al.*, “Catalyzed Relaxation of a Metastable DNA Fuel”; *J. Am. Chem. Soc.* 2006, 128(37), pp 12211-12220). A FOV can be reimaged to confirm that all complementary nucleic acids having detectable labels are removed before moving continuing. This takes about fifteen seconds. This step can be repeated until background signal levels are reached.

[00165] The above steps are repeated or the remaining positions in the probes’ barcode domain.

[00166] The total time to read equals m (bases read) *times* (15 sec + n FOVs *times* 1 sec + 15 sec). For example, when the number of positions in the barcode domain is 6 and 20 FOVs, the time to read equals $6 \times (30 + 20 + 15)$ or 390 seconds.

[00167] Probes of the first population are de-hybridized. This takes about sixty seconds.

[00168] The above steps are repeated for second and subsequent populations of probes. If populations of sequencing probes are organized by melting temperature (T_m), each population of probes will require multiple hybridizations to ensure that each base is covered to required depth (this is driven by error rate). Moreover, by analyzing the hybridization reads during a run, it is possible to recognize each individual gene that is being sequenced well before the entire sequence is actually determined. Hence cycling can be repeated until a particular desired error-frequency (or coverage) is met.

[00169] Using the timing described above, together with some gapped-nucleic acid binding density estimates, throughput of a Nanostring (NSTG)-Next Generation Sequencer of the present invention can be estimated.

[00170] Net throughput of sequencer is given by:

$$\text{Fractional-Base-Occupancy} \times \text{<gap-length>} \times \text{number-of-gaps-per-FOV} \times \text{number-of-bases-per-optical-barcode} / [60 \text{ sec (hybridizing probes to target nucleic acid)} + 0.5 \text{ sec (wash)} + m: \text{ positions in the barcode domain} \times (15 \text{ sec (binding complementary nucleic acids)} + n\text{fovs} \times 1 + 15 \text{ sec (unbinding complementary nucleic acids)}) + 60 \text{ sec (de-hybridizing probes to target nucleic acid)}]$$

[00171] Therefore, in an example, a total “cycle” for a single gapped-nucleic acid (adding together from the method shown in Figure 10):

$$60 \text{ sec (hybridizing probes to target nucleic acid)} + 0.5 \text{ sec (wash)} + m\text{-bases} \times (15 \text{ sec (binding complementary nucleic acids)} + n\text{FOVs} \times 1 + 15 \text{ sec (unbinding complementary nucleic acids)}) + 60 \text{ sec (de-hybridizing probes to target nucleic acid)}.$$

Using $m = 6$, $n\text{FOVs} = 20$, yields time = $60 + 0.5 + 390 + 60 = 510.5 \text{ sec}$.

[00172] Assuming: 1% occupancy of the gapped-nucleic acid region, 4000 bases per gap, and 5000 gapped nucleic-acid fragments per FOV and an m of 6 and $n\text{FOVs}$ of 20 (as described above) yields a net throughput of:

$$0.01 \times 4000 \times 5000 \times 20 = 4,000,000 \text{ 6-base reads per } 510.5 \text{ secs} = 47,012.73 \text{ bases/sec.}$$

[00173] Therefore, in this example, a net throughput per 24 hours of continuous measurement = 4.062 Gigabases (Gb) per day. Alternate estimates up to 12 Gb per day. *See* Figure 12.

[00174] As shown in Figure 14, the run-time required to sequence 100 different target nucleic acids (a “100-plex”) is about 4.6 hours; the run-time required to sequence 1000 different target nucleic acids (a “1000-plex”) is about 16 hours.

[00175] Figure 16 compares the sequencing rate, number of reads, and clinical utility for the present invention and various other sequencing methods/ apparatuses.

Example 2: The present invention’s method has a low error rate

[00176] Figure 17 shows that the present invention has a raw error rate of about 2.1%, when terminal positions are omitted.

[00177] For the claimed invention, an error rate associated with sequencing is related to the free-energy difference between a fully-matched (m+n)-mer and a single-base mismatch (m-1+n)-mer. The sum of m+n is the number of nucleotides in a target binding domain and m represents the number of positions in a barcode domain. An estimate of the selectivity of hybridization can be made using the equation (See, Owczarzy, R. (2005), *Biophys. Chem.*, 117:207-215 and Integrated DNA Technologies website: at the World Wide Web (www.idtdna.com/analyzer/Applications/Instructions/Default.aspx?AnalyzerDefinitions=true#MismatchMeltTemp)).

$$\theta = 1 - \left(\frac{K_a([strand2] - [strand1]) - 1}{2K_a[strand2]} + \frac{\sqrt{K_a^2([strand1] - [strand2])^2 + 2K_a([strand1] + [strand2]) + 1}}{2K_a[strand2]} \right)$$

where K_a is the association equilibrium constant obtained from predicted thermodynamic parameters,

$$K_a = \exp \left(\frac{-(\Delta H^\circ - T\Delta S^\circ)}{RT} \right)$$

[00178] Theta represents the percent bound of the exact complement and the single base mismatch sequences, which are expected to be annealed to target at the specified hybridization temperature. The T is the hybridization temperature in Kelvins, ΔH° (enthalpy) and ΔS° (entropy) are the melting parameters calculated from the sequence and the published nearest neighbor thermodynamic parameters, R is the ideal gas constant ($1.987 \text{ cal} \cdot \text{K}^{-1} \cdot \text{mole}^{-1}$), $[strand1/2]$ is the molar concentration of an oligonucleotide, and the constant of -273.15 converts temperature from Kelvin to degrees of Celsius. The most accurate, nearest-neighbor parameters were obtained from the following publications for DNA/DNA base pairs (See, Allawi, H., SantaLucia, J. *Biochemistry*, 36, 10581), RNA/DNA base pairs (See, Sugimoto *et al.*, *Biochemistry*, 34, 11211-6), RNA/RNA base pairs (See, Xia, T. *et al.*, *Biochemistry*, 37, 14719),

[00179] As example of an estimate of the approximate error-rate expected from the NSTG-sequencer follows. For (m + n) equals 8' mer. Consider the following 8-mer barcode and its single-base mismatch.

5'ATCGTACG3'

(region to sequence)

3'TAGCATGC5'

(sequencing optical barcode with perfect match)

3'TAGTATGC5'

(sequencing optical barcode with single-base mismatch (G-T) pairing)

[00180] Using the IDT calculator based upon the above equations yields:

[00181] At 17.4°C (the T_m of the perfect match case), (50% / 0.3%) would be the ratio of the correct optical barcode hybridized to that sequence versus the incorrect barcode at the T_m , yielding an estimated error rate for that sequence to be 0.6%.

[00182] A very high GC content sequencing calculation yields:

5'CGCCGGCC3'

(region to sequence)

3'GCGGCCGG5'

(sequencing optical barcode with perfect match)

3'GCGGACGG5'

(sequencing optical barcode with single-base mismatch (G-A) mis-pairing)

[00183] At 41.9°C (the T_m of the perfect match case), (50% / 0.4%) would be the ratio of the correct optical barcode hybridized to that sequence versus the incorrect barcode at the T_m , yielding an estimated error rate for that sequence to be 0.8%.

[00184] Examination of a number of 8-mer pairs yields a distribution of error rates, in the range of 0.2% to 1%. While the above calculations will not be identical to the conditions used, these calculations provide an indication that the method of the present invention will have a relatively low intrinsic error rate, when compared to other single-molecule sequencing technologies, such as Pacific Biosciences and Oxford Nanopore Technologies where error rates can be significant (>> 10%).

[00185] Figure 18 demonstrates that the present invention's raw accuracy is higher than other sequencing methods. Thus, the present invention provides a consensus sequence from a single target after fewer passes than required for other sequencing methods. Additionally, the present

invention may obtain “perfect consensus”/“error-free” sequencing (i.e., 99.9999%/Q60) after 30 or more passes whereas the PacBio sequencing methods (for example) cannot attain such a consensus after 70 passes.

Example 3: The present invention has single base-pair resolution ability

[00186] Figure 19 shows that the present invention has single-base resolution and with low error rates (ranging from 0% to 1.5% depending on a specific nucleotide substitution).

[00187] Additional experiments were performed using a target RNA hybridized with barcode and immobilized to the surface of cartridge using normal NanoString gene-expression binding technology (*see, e.g., Geiss et al, “Direct multiplexed measurement of gene expression with color-coded probe pairs”; Nature Biotechnology, 26, 317 - 325 (2008)*). The ability of a barcode with different target binding domain length and with a perfect match (YGBYGR-2um optical bar code connected to perfect 10-mer match sequence) to hybridize to RNA-target was measured (Figure 26). Longer length of target binding domain gives higher counts. It also shows that 10-mer target binding domain is enough to register the sequence above background. Each of the individual single-base altered matches was synthesized with alternate optical bar codes. The ratio of correct to incorrect optical barcodes was counted (Figures 24 and 25).

[00188] Ability of 10mer to detect a SNP the real sequence is >15000 counts over background, whilst incorrect sequences are at most > 400 over background. In the presence of correct probe, error rates are expected to be <3% of real sequence. Note that this data is (in essence) a worse-case scenario. Having only a 10-base-pair hybridization sequence attached to a 6.6 Kilobase optical barcode reporter (Gen2 style). No specific condition optimizations were performed. This data, however, does reveal that the NanoString Next-Generation Sequencing approach is capable of resolving single-base pairs of sequence.

[00189] The detailed materials and methods utilized in the above study are as follows:

[00190] Hybridization Protocol Probe B plus codeset

- Take 25ul elements (194 codeset)
- Add 5ul Probe B+ complimentary sequence to target (100uM)
- Add 15ul Hyb Buffer (14.56 X SSPE 0.18% Tween 20)

SSPE (150mM NaCl, NaH₂PO₄xH₂O 10mM, Na₂EDTA 10mM)

- Incubate on ice for 10 min
- Add 150ul G beads(40ul G beads at 10mg/ml plus 110 ul 5x SSPE 0.1% Tween 20)
- Incubate for 10 min at RT
- Wash three times with 0.1SSPE 0.1% Tween 20 using magnet collector
- Elute in 100ul 0.1x SSPE for 10 min at 45C.

[00191] Target Hybridization protocol (750mM NaCl)

- Take 20 ul above eluted sample
- Add 10 ul hyb buffer
- Add 1ul Target (100nM biotinylated RNA)
- Incubate on ice for 30 min

Take 15ul and Bind to streptavidin slide for 20 min, flow stretch with G hooks, count using nCounter

[00192] Materials

Elements 194 codeset

Oligos bought from IDT

SSPE (150mM NaCl, NaH₂PO₄·H₂O 10mM, Na₂EDTA 10mM)

Hyb buffer (14.56 X SSPE 0.18% Tween 20)

[00193] Table 2: Probe B Sequences for 12, 11, ..., 8 mers. (SEQ ID NO: 30 to SEQ ID NO: 34)

GBRYBG	5	GACTGTACCCACGCGATGACGTTTCGTC AAGAGTCGCATAATCT	3
YRBYRG	5	AGACTGTACCACAAGAATCCCTGCTAGCTGAAGGAGGGTCAAAC	3
YGBYGR	5	GAGACTGTACCCTACGTATATATCCAAGTGGTTATGTCCGACGGC	3
GBRYGB	5	TGAGACTGTACCACCCCTCCAAACGCATTCTTATTGGCAAATGGAA	3
RYGBRG	5	CTGAGACTGTACCCGGGAATCGGCATTTCGCATTCTTAGGATCTAAA	3

[00194] Table 3: Target Sequence (in **Bold**; SEQ ID NO: 35)

RNA	5	CAATGTGAGTCTCTTGGTACAGTCTCAGTTAGTCACTCCCTAAG\ Bio TEG\	3
-----	---	--	---

[00195] Table 4: Probe B Sequences for 10mer mismatches (in **Bold**; SEQ ID NO: 36 to SEQ ID NO: 41)

10mermis2A	GAGACAGTACCCTGGTCTAGGTATCTAATTCGTGGGTCGGGTACT
------------	---

10mermis2C	GAGACCGTACCGCTCATTTTGAACATACGATTGCGATTACGGAAA
10mermis2G	GAGACGGTACCTTAAAGCTATCCACGAATGTCAAAAATGTGGTTT
10mermis1G	GAGAGTGTACCCAATGCTTGCAGTATGTATCCTGATCGTGCGTGC
10mermis1A	GAGAATGTACCCTCATACCAATGTAAAGTATAGTTAACGCCCTGT
10mermis1T	GAGATTGTACCCTACATATATAGGAAAAGGGAAGGTAGAAGAGC T

What is claimed is:

1. A sequencing probe comprising a target binding domain and a barcode domain;
wherein said target binding domain comprises at least four nucleotides and is capable of binding a target nucleic acid;
wherein said barcode domain comprises a synthetic backbone, said barcode domain comprising at least a first attachment region, said first attachment region comprising a nucleic acid sequence capable of being bound by a first complementary nucleic acid molecule and wherein said nucleic acid sequence of said first attachment region determines the position and identity of a first nucleotide in said target nucleic acid that is bound by a first nucleotide of said target binding domain.
2. The sequencing probe of claim 1, wherein said synthetic backbone comprises a polysaccharide, a polynucleotide, a peptide, a peptide nucleic acid, or a polypeptide.
3. The sequencing probe of claim 1 or claim 2, wherein said synthetic backbone comprises single stranded-stranded DNA.
4. The sequencing probe of any of claims 1 to 3, wherein said sequencing probe comprises a double-stranded DNA spacer between the target binding domain and the barcode domain.
5. The sequencing probe of any of claims 1 to 3 wherein said sequencing probe comprises a polymer-based spacer with similar mechanical properties as a double-stranded DNA between the target binding domain and the barcode domain.
6. The sequencing probe of any of claims 4 to 5, wherein said double-stranded DNA spacer has a length between 1 base-pair and 100 base-pair.
7. The sequencing probe of any of claims 4 to 6, wherein said double-stranded DNA spacer has length between 2 base-pair and 50 base-pair.

8. The sequencing probe of any of claims 1 to 7, wherein said first attachment region is adjacent to at least one flanking single-stranded polynucleotide.
9. The sequencing probe of any of claims 1 to 8, wherein the first complementary nucleic acid is RNA, DNA or PNA.
10. The sequencing probe of any of claims 1 to 9, wherein the first complementary nucleic molecule comprises a detectable label.
11. The sequencing probe of any of claims 1 to 9, wherein the first nucleotide in said target binding domain is a modified nucleotide or a nucleic acid analogue.
12. The sequencing probe of any of claims 1 to 11, wherein said barcode domain comprises at least a second attachment region, said second attachment region comprising a nucleic acid sequence capable of being bound by a second complementary nucleic acid molecule and wherein said nucleic acid sequence of said second attachment region determines the position and identity of a second nucleotide in said target nucleic acid that is bound by a second nucleotide of said target binding domain and
wherein the first complementary nucleic acid molecule is different from the second complementary nucleic acid molecule.
13. The sequencing probe of claim 12, wherein said second attachment region is adjacent to at least one flanking single-stranded polynucleotide.
14. The sequencing probe of claim 12, wherein the second complementary nucleic acid is RNA, DNA or PNA.
15. The sequencing probe of any of claims 14, wherein the second complementary nucleic molecule comprises a detectable label.
16. The sequencing probe of claim 12, wherein the second nucleotide in said target binding

domain is a modified nucleotide or a nucleic acid analogue.

17. The sequencing probe of claim 12, wherein the nucleic acid sequence of the first attachment region that determines the position and identity of the first nucleotide in the target nucleic acid and the nucleic acid sequence of the second attachment region that determines the position and identity of the second nucleotide in the target nucleic acid are different even when the first nucleotide in the target nucleic acid and the second nucleotide in the target nucleic acid are identical.

18. The sequencing probe of any of claims 1 to 17, wherein the number of nucleotides in a target binding domain equals the number of attachment regions in the barcode domain.

19. The sequencing probe of any of claims 1 to 17, wherein the number of nucleotides in a target binding domain is at least one more than the number of attachment regions in the barcode domain.

20. The sequencing probe of claim 19, wherein the number of nucleotides in a target binding domain is at least two more than the number of attachment regions in the barcode domain.

21. The sequencing probe of claim 20, wherein the number of nucleotides in a target binding domain is at least three more than the number of attachment regions in the barcode domain.

22. The sequencing probe of claim 21, wherein the number of nucleotides in a target binding domain is at least four more than the number of attachment regions in the barcode domain.

23. The sequencing probe of claim 22, wherein the number of nucleotides in a target binding domain is at least five more than the number of attachment regions in the barcode domain.

24. The sequencing probe of claim 23, wherein the number of nucleotides in a target binding domain is at least six more than the number of attachment regions in the barcode domain.

25. The sequencing probe of claim 24, wherein the number of nucleotides in a target binding domain is at least seven more than the number of attachment regions in the barcode domain.
26. The sequencing probe of claim 17, wherein the target binding domain comprises at least seven nucleotides and is capable of binding the target nucleic acid.
27. The sequencing probe of claim 26, wherein the number of nucleotides in a target binding domain is at least one more than the number of attachment regions in the barcode domain.
28. The sequencing probe of claim 26, wherein the target binding domain comprises at least ten nucleotides and is capable of binding the target nucleic acid.
29. The sequencing probe of claim 28, wherein the number of nucleotides in a target binding domain is at least one more than the number of attachment regions in the barcode domain.
30. The sequencing probe of claim 28, wherein the target binding domain comprises ten nucleotides and the barcode domain comprises six attachment regions.
31. The sequencing probe of claim 1, wherein the barcode domain comprises at least two first attachment regions, wherein the at least two first attachment regions comprise an identical nucleic acid sequence that is capable of being bound by a first complementary nucleic acid molecule and that determines the position and identity of a first nucleotide in the target nucleic acid that is bound by a first nucleotide of said target binding domain.
32. The sequencing probe of claim 31, wherein each position in a barcode domain has the same number of attachment regions.
33. The sequencing probe of claim 1, wherein each position in a barcode domain has the same number of attachment regions.
34. The sequencing probe of claim 33, wherein each position in a barcode domain has one

attachment region.

35. The sequencing probe of claim 33, wherein each position in a barcode domain has more than one attachment region.

36. The sequencing probe of claim 1, wherein at least one position in a barcode domain has a greater number of attachment regions as another position.

37. The sequencing probe of any of claims 1 to 36, wherein the first attachment region is linked to a modified monomer in the synthetic backbone.

38. The sequencing probe of claim 37, wherein the modified monomer is a modified nucleotide.

39. The sequencing probe of any of claims 1 to 38, wherein the first attachment region branches from the synthetic backbone.

40. The sequencing probe of claim 12, wherein the second attachment region branches from the synthetic backbone.

41. The sequencing probe of claim 17, wherein each of the at least six attachment regions branches from the synthetic backbone.

42. The sequencing probe of claim of any of claims 1 to 41, wherein the target binding domain and the synthetic backbone are operably linked.

43. The sequencing probe of claim 12, wherein said barcode domain comprises at least a third attachment region, said third attachment region comprising a nucleic acid sequence capable of being bound by a third complementary nucleic acid molecule and wherein said nucleic acid sequence of said third attachment region determines the position and identity of a third nucleotide in said target nucleic acid that is bound by a third nucleotide of said target binding

domain and

wherein the third complementary nucleic acid molecule is different from the first and the second complementary nucleic acid molecules.

44. The sequencing probe of claim 43, wherein said third attachment region is adjacent to at least one flanking single-stranded polynucleotide.

45. The sequencing probe of claim 43, wherein said barcode domain comprises at least a fourth attachment region, said fourth attachment region comprising a nucleic acid sequence capable of being bound by a fourth complementary nucleic acid molecule and wherein said nucleic acid sequence of said fourth attachment region determines the position and identity of a fourth nucleotide in said target nucleic acid that is bound by a fourth nucleotide of said target binding domain and

wherein the fourth complementary nucleic acid molecule is different from the first, the second, and the third complementary nucleic acid molecules.

46. The sequencing probe of claim 45, wherein said fourth attachment region is adjacent to at least one flanking single-stranded polynucleotide.

47. The sequencing probe of claim 45, wherein said barcode domain comprises at least a fifth attachment region, said fifth attachment region comprising a nucleic acid sequence capable of being bound by a fifth complementary nucleic acid molecule and wherein said nucleic acid sequence of said fifth attachment region determines the position and identity of a fifth nucleotide in said target nucleic acid that is bound by a fifth nucleotide of said target binding domain and

wherein the fifth complementary nucleic acid molecule is different from the first, the second, the third, and the fourth complementary nucleic acid molecules.

48. The sequencing probe of claim 47, wherein said fifth attachment region is adjacent to at least one flanking single-stranded polynucleotide.

49. The sequencing probe of claim 47, wherein said barcode domain comprises at least a

sixth attachment region, said sixth attachment region comprising a nucleic acid sequence capable of being bound by a sixth complementary nucleic acid molecule and wherein said nucleic acid sequence of said sixth attachment region determines the position and identity of a sixth nucleotide in said target nucleic acid that is bound by a sixth nucleotide of said target binding domain and

wherein the sixth complementary nucleic acid molecule is different from the first, the second, the third, the fourth, and the fifth complementary nucleic acid molecules.

50. The sequencing probe of claim 49, wherein said sixth attachment region is adjacent to at least one flanking single-stranded polynucleotide.

51. The sequencing probe of any of claims 1 to 50, wherein an attachment region comprises one to fifty copies of a nucleic acid sequence.

52. The sequencing probe of claim 51, wherein the attachment region comprises two to thirty copies of the nucleic acid sequence.

53. The sequencing probe of any of claim 1 to 52 comprising multiple copies of the target binding domain operably linked to a synthetic backbone.

54. The sequencing probe of any of claims 1 to 53, wherein each complementary nucleic acid molecule comprises a detectable label.

55. The sequencing probe of any of claims 1 to 54, wherein each complementary nucleic acid molecule is directly linked to a primary nucleic acid molecule.

56. The sequencing probe of any of claims 1 to 54, wherein each complementary nucleic acid molecule is indirectly linked to a primary nucleic acid molecule via a nucleic acid spacer.

57. The sequencing probe of claim 55 or claim 56, wherein each complementary nucleic acid molecule comprises between about 8 nucleotides and about 20 nucleotides.

58. The sequencing probe of claim 57, wherein each complementary nucleic acid molecule comprises about 10 nucleotides.
59. The sequencing probe of claim 58, wherein each complementary nucleic acid molecule comprises about 12 nucleotides.
60. The sequencing probe of claim 59, wherein each complementary nucleic acid molecule comprises about 14 nucleotides.
61. The sequencing probe of any of claims 55 to 60, wherein each primary nucleic acid molecule is hybridized to at least one secondary nucleic acid molecule.
62. The sequencing probe of claim 61, wherein each primary nucleic acid molecule is hybridized to at least two secondary nucleic acid molecules.
63. The sequencing probe of claim 62, wherein each primary nucleic acid molecule is hybridized to at least three secondary nucleic acid molecules.
64. The sequencing probe of claim 63, wherein each primary nucleic acid molecule is hybridized to at least four secondary nucleic acid molecules.
65. The sequencing probe of claim 64, wherein each primary nucleic acid molecule is hybridized to at least five secondary nucleic acid molecules.
66. The sequencing probe of any of claims 61 to 65, wherein the secondary nucleic acid molecule or molecules comprise at least one detectable label.
67. The sequencing probe of any of claims 61 to 65, wherein each secondary nucleic acid molecule is hybridized to at least one tertiary nucleic acid molecule comprising at least one detectable label.

68. The sequencing probe of claim 67 wherein each secondary nucleic acid molecule is hybridized to at least two tertiary nucleic acid molecules comprising at least one detectable label.

69. The sequencing probe of claim 68, wherein each secondary nucleic acid molecule is hybridized to at least three tertiary nucleic acid molecules comprising at least one detectable label.

70. The sequencing probe of claim 69, wherein each secondary nucleic acid molecule is hybridized to at least four tertiary nucleic acid molecules comprising at least one detectable label.

71. The sequencing probe of claim 70, wherein each secondary nucleic acid molecule is hybridized to at least five tertiary nucleic acid molecules comprising at least one detectable label.

72. The sequencing probe of claim 71, wherein each secondary nucleic acid molecule is hybridized to at least six tertiary nucleic acid molecules comprising at least one detectable label.

73. The sequencing probe of claim 71, wherein each secondary nucleic acid molecule is hybridized to at least seven tertiary nucleic acid molecules comprising at least one detectable label.

74. The sequencing probe of any of claims 61 to 71, wherein at least one secondary nucleic acid molecule comprises a region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule.

75. The sequencing probe of claim 74, wherein each secondary nucleic acid molecule comprises a region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule.

76. The sequencing probe of claim 74 or claim 75, wherein the region that does not hybridize

to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule comprises the nucleotide sequence of the complementary nucleic acid molecule that is linked to the primary nucleic acid molecule.

77. The sequencing probe of any of claims 74 to 76, wherein the region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule is located at a terminus of the secondary nucleic acid molecule.

78. The sequencing probe of any of claims 74 to 77, wherein the region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule comprises between about 8 nucleotides and about 20 nucleotides.

79. The sequencing probe of claim 78, wherein the region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule comprises about 10 nucleotides.

80. The sequencing probe of claim 79, wherein the region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule comprises about 12 nucleotides

81. The sequencing probe of claim 80, wherein the region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule comprises about 14 nucleotides

82. A method for sequencing a nucleic acid comprising steps of:

(1) hybridizing at least one sequencing probe to a target nucleic acid that is immobilized to a substrate; wherein said sequencing probe comprises:

a target binding domain and a barcode domain;

wherein said target binding domain comprises at least four nucleotides and is capable of binding the immobilized target nucleic acid;

wherein said barcode domain comprises a synthetic backbone, said barcode

domain comprising at least a first attachment region, said first attachment region comprising a nucleic acid sequence capable of being bound by a first complementary nucleic acid molecule and wherein said nucleic acid sequence of said first attachment region determines the position and identity of a first nucleotide in said immobilized target nucleic acid that is bound by a first nucleotide of said target binding domain and

(2) binding to the first attachment region a first complementary nucleic acid molecule comprising a detectable label or a first complementary nucleic acid molecule of a first reporter complex comprising a detectable label;

(3) detecting the detectable label of the bound first complementary nucleic acid molecule or the detectable label of the bound first complementary nucleic acid molecule of the first reporter complex; and

(4) identifying the position and identity of the first nucleotide in the immobilized target nucleic acid.

83. The method of 82, further comprising steps of:

(5) contacting the first attachment region with a first hybridizing nucleic acid molecule lacking a detectable label thereby unbinding the first complementary nucleic acid molecule and binding to the first attachment region the first hybridizing nucleic acid molecule lacking a detectable label;

(6) binding to the second attachment region a second complementary nucleic acid molecule comprising a detectable label or a second complementary nucleic acid molecule of a second reporter complex comprising a detectable label, said second attachment region comprising a nucleic acid sequence that determines the position and identity of a second nucleotide in the immobilized target nucleic acid that is bound by a second nucleotide of the target binding domain;

(7) detecting the detectable label of the bound second complementary nucleic acid molecule or the detectable label of the bound second complementary nucleic acid molecule of the second reporter complex; and

(8) identifying the position and identity of the second nucleotide in the immobilized target nucleic acid.

84. The method of claim 82 or claim 83, wherein steps (5) and (6) occur sequentially or concurrently.

85. The method of any of claims 82 to 84, wherein steps (5) to (8) are repeated until each attachment region in the barcode domain has been sequentially bound by a complementary nucleic acid molecule comprising a detectable label or a complementary nucleic acid molecule of a reporter complex comprising a detectable label, and the detectable label of the sequentially bound complementary nucleic acid molecule or the detectable label of the sequentially bound complementary nucleic acid molecule of a reporter complex has been detected,

thereby identifying the linear order of nucleotides for a region of the immobilized target nucleic acid that was hybridized by the target binding domain of the sequencing probe.

86. The method of any of claims 82 to 85, wherein the target nucleic acid is first immobilized to a substrate by at least binding a first position of the target nucleic acid with a first capture probe that comprises a first affinity tag that selectively binds to a substrate.

87. The method of claim 86, wherein the target nucleic acid is elongated by applying a force sufficient to extend the target nucleic acid that is immobilized to a substrate at a first position.

88. The method of claim 87, wherein the force is gravity, hydrodynamic force, electromagnetic force, flow-stretching, a receding meniscus technique, or combinations thereof.

89. The method of any of claims 86 to 88, wherein the target nucleic acid is further immobilized to a substrate by binding an at least second position of the target nucleic acid with an at least second capture probe that comprises an affinity tag that selectively binds to the substrate.

90. The method of claim 89, wherein the target nucleic acid is immobilized to a substrate at about three to about ten position.

91. The method of claim 89, wherein the force can be removed once the second position of

the target nucleic acid is immobilized to the substrate.

92. The method of claim 82, wherein said target nucleic acid is immobilized to a substrate at one or more positions.

93. The method of any of claims 82 to 92, wherein said immobilized target nucleic acid is elongated.

94. The method of any of claims 82 to 93, wherein said synthetic backbone comprises a polysaccharide, a polynucleotide, a peptide, a peptide nucleic acid, or a polypeptide.

95. The method of any of claims 82 to 94, wherein said synthetic backbone comprises single stranded-stranded DNA or single-stranded RNA or single-stranded PNA.

96. The method of any of claims 82 to 95, wherein said sequencing probe comprises a double-stranded DNA spacer between the target binding domain and the barcode domain.

97. The method of any of claims 82 to 96, wherein said first attachment region is adjacent to at least one flanking single-stranded polynucleotide.

98. The method of any of claims 82 to 97, wherein the first complementary nucleic acid is RNA, DNA or PNA or other polynucleotide analogue.

99. The method of any of claims 82 to 98, wherein the first nucleotide in said target binding domain is a modified nucleotide or a nucleic acid analogue.

100. The method of claim 82, wherein said barcode domain comprises at least a second attachment region, said second attachment region comprising a nucleic acid sequence capable of being bound by a second complementary nucleic acid molecule and wherein said nucleic acid sequence of said second attachment region determines the position and identity of a second nucleotide in said immobilized target nucleic acid that is bound by a second nucleotide of said

target binding domain and

wherein the first complementary nucleic acid molecule is different from the second complementary nucleic acid molecule.

101. The method of claim 100, wherein said second attachment region is adjacent to at least one flanking single-stranded polynucleotide or polynucleotide analogue.

102. The method of claim 100, wherein the second complementary nucleic acid is RNA, DNA or PNA.

103. The method of claim 100, wherein the second nucleotide in said target binding domain is a modified nucleotide or a nucleic acid analogue.

104. The method of any of claims 83 to 103, wherein the first complementary nucleic acid molecule and the first hybridizing nucleic acid molecule lacking a detectable label comprise the same nucleic acid sequence.

105. The method of any of claims 82 to 104, wherein the first hybridizing nucleic acid molecule lacking a detectable label comprises a nucleic acid sequence complementary to a flanking single-stranded polynucleotide adjacent to said first attachment region.

106. The method of claim 105, wherein said target binding domain comprises at least three nucleotides and wherein the barcode domain comprises at least a third attachment region, said third attachment region comprising a nucleic acid sequence capable of being bound by a third complementary nucleic acid molecule and wherein said nucleic acid sequence of said third attachment region determines the position and identity of a third nucleotide in said target nucleic acid that is bound by a third nucleotide of said target binding domain.

107. The method of claim 106, wherein said third attachment region is adjacent to at least one flanking single-stranded polynucleotide or polynucleotide analogue.

108. The method of claim 106 or claim 107, wherein said target binding domain comprises at least four nucleotides and wherein the barcode domain comprises at least a fourth attachment region, said fourth attachment region comprising a nucleic acid sequence capable of being bound by a fourth complementary nucleic acid molecule and wherein said nucleic acid sequence of said fourth attachment region determines the position and identity of a fourth nucleotide in said target nucleic acid that is bound by a fourth nucleotide of said target binding domain.

109. The method of claim 108, wherein said fourth attachment region is adjacent to at least one flanking single-stranded polynucleotide.

110. The method of claim 108 or claim 109, wherein said target binding domain comprises at least five nucleotides and wherein the barcode domain comprises at least a fifth attachment region, said fifth attachment region comprising a nucleic acid sequence capable of being bound by a fifth complementary nucleic acid molecule and wherein said nucleic acid sequence of said fifth attachment region determines the position and identity of a fifth nucleotide in said target nucleic acid that is bound by a fifth nucleotide of said target binding domain.

111. The method of claim 110, wherein said fifth attachment region is adjacent to at least one flanking single-stranded polynucleotide.

112. The method of claim 110 or claim 111, wherein said target binding domain comprises at least six nucleotides and the barcode domain comprises at least a sixth attachment region, said sixth attachment region comprising a nucleic acid sequence capable of being bound by a sixth complementary nucleic acid molecule and wherein said nucleic acid sequence of said sixth attachment region determines the position and identity of a sixth nucleotide in said target nucleic acid that is bound by a sixth nucleotide of said target binding domain.

113. The method of claim 112, wherein said sixth attachment region is adjacent to at least one flanking single-stranded polynucleotide.

114. The method of any of claims 82 to 113, wherein the number of nucleotides in a target

binding domain equals the number of attachment regions in the barcode domain.

115. The method of any of claims 82 to 113, wherein the number of nucleotides in a target binding domain is at least one more than the number of attachment regions in the barcode domain.

116. The method of any of claims 82 to 113, wherein at least the first attachment region branches from the synthetic backbone.

117. The method of claim 116, wherein the second attachment region branches from the synthetic backbone.

118. The method of claim 117, wherein each of the at least a six attachment regions branches from the synthetic backbone.

119. The method of any of claims 82 to 118, wherein the barcode domain comprises at least two first attachment regions, wherein the at least two first attachment regions comprise an identical nucleic acid sequence that is capable of being bound by a first complementary nucleic acid molecule and that determines the position and identity of a first nucleotide in the target nucleic acid that is bound by a first nucleotide of said target binding domain.

120. The method of claim 119, wherein each position in a barcode domain has the same number of attachment regions.

121. The method of claim 82, wherein each position in a barcode domain has the same number of attachment regions.

122. The method of claim 121, wherein each position in a barcode domain has one attachment region.

123. The method of claim 121, wherein each position in a barcode domain has more than one

attachment region.

124. The method of claim 82, wherein at least one position in a barcode domain has a greater number of attachment regions as another position.

125. The method of any of claims 82 to 124, wherein an attachment region comprises one to fifty copies of a nucleic acid sequence.

126. The method of claim 125, wherein the attachment region comprises two to thirty copies of the nucleic acid sequence.

127. The method of any of claim 82 to 126, wherein the sequencing probe comprises multiple copies of the target binding domain operably linked to a synthetic backbone.

128. The method of any of claims 82 to 127, wherein each reporter complex comprising a detectable label comprises a complementary nucleic acid molecule directly linked to a primary nucleic acid molecule.

129. The method of any of claims 80 to 128, wherein each reporter complex comprising a detectable label comprises a complementary nucleic acid molecule indirectly linked to a primary nucleic acid molecule via a nucleic acid spacer.

130. The method of any of claims 82 to 129, wherein each reporter complex comprising a detectable label comprises a complementary nucleic acid molecule indirectly linked to a primary nucleic acid molecule via a polymeric spacer with a similar mechanical properties as nucleic acid spacer.

131. The method of any one of claims 82 to 130, wherein each complementary nucleic acid molecule comprises between about 8 nucleotides and about 20 nucleotides.

132. The method of any one of claims 82 to 131, wherein each complementary nucleic acid

molecule comprises about 10 nucleotides.

133. The method of any one of claims 82 to 132, wherein each complementary nucleic acid molecule comprises about 12 nucleotides.

134. The method of any one of claims 82 to 133, wherein each complementary nucleic acid molecule comprises about 14 nucleotides.

135. The method of any of claims 82 to 134, wherein each primary nucleic acid molecule is hybridized to at least one secondary nucleic acid molecule.

136. The method of claim 135, wherein each primary nucleic acid molecule is hybridized to at least two secondary nucleic acid molecules.

137. The method of claim 136, wherein each primary nucleic acid molecule is hybridized to at least three secondary nucleic acid molecules.

138. The method of claim 137, wherein each primary nucleic acid molecule is hybridized to at least four secondary nucleic acid molecules.

139. The method of claim 138, wherein each primary nucleic acid molecule is hybridized to at least five secondary nucleic acid molecules.

140. The sequencing probe of any of claims 135 to 139, wherein the secondary nucleic acid molecule or molecules comprise at least one detectable label.

141. The method of any of claims 135 to 139, wherein each secondary nucleic acid molecule is hybridized to at least one tertiary nucleic acid molecule comprising at least one detectable label.

142. The method of claim 141, wherein each secondary nucleic acid molecule is hybridized to

at least two tertiary nucleic acid molecules comprising at least one detectable label.

143. The method of claim 142, wherein each secondary nucleic acid molecule is hybridized to at least three tertiary nucleic acid molecules comprising at least one detectable label.

144. The method of claim 143, wherein each secondary nucleic acid molecule is hybridized to at least four tertiary nucleic acid molecules comprising at least one detectable label.

145. The method of claim 144, wherein each secondary nucleic acid molecule is hybridized to at least five tertiary nucleic acid molecules comprising at least one detectable label.

146. The method of claim 145, wherein each secondary nucleic acid molecule is hybridized to at least six tertiary nucleic acid molecules comprising at least one detectable label.

147. The method of claim 146, wherein each secondary nucleic acid molecule is hybridized to at least seven tertiary nucleic acid molecules comprising at least one detectable label.

148. The method of any of claims 135 to 147, wherein at least one secondary nucleic acid molecule comprises a region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule.

149. The method of claim 148, wherein each secondary nucleic acid molecule comprises a region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule.

150. The method of claim 148 or claim 149, wherein the region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule comprises the nucleotide sequence of the complementary nucleic acid molecule that is directly linked to the primary nucleic acid molecule.

151. The method of any of claims 148 to 150, wherein the region that does not hybridize to a

primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule is located at a terminus of the secondary nucleic acid molecule.

152. The method of any of claims 148 to 151, wherein the region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule comprises between about 8 nucleotides and about 20 nucleotides.

153. The method of claim 152, wherein the region that does not hybridize to a primary nucleic acid molecule and does not hybridize to a tertiary nucleic acid molecule comprises about 12 nucleotides.

154. A method for sequencing a nucleic acid comprising steps of:

(1) hybridizing a first population of sequencing probes to a target nucleic acid that is immobilized to a substrate, wherein each sequencing probe in the first population comprises:

a target binding domain and a barcode domain;

wherein said target binding domain comprises at least four nucleotides and is capable of binding a target nucleic acid;

wherein said barcode domain comprises a synthetic backbone, said barcode domain comprising a first attachment region, said first attachment region comprising a nucleic acid sequence capable of being bound by a first complementary nucleic acid molecule and wherein said nucleic acid sequence of said first attachment region determines the position and identity of a first nucleotide in said target nucleic acid that is bound by a first nucleotide of said target binding domain and

said barcode domain further comprising at least a second attachment region, said second attachment region comprising a nucleic acid sequence capable of being bound by a second complementary nucleic acid molecule and wherein said nucleic acid sequence of said second attachment region determines the position and identity of a second nucleotide in said target nucleic acid that is bound by a second nucleotide of said target binding domain and

wherein the first complementary nucleic acid molecule is different from the second complementary nucleic acid molecule;

wherein each sequencing probe in the first population de-hybridizes from the immobilized target nucleic acid under about the same conditions;

(2) binding to a first attachment region in each sequencing probe in the first population a plurality of first complementary nucleic acid molecules each comprising a detectable label or a plurality of first complementary nucleic acid molecules of a plurality of first reporter complexes each complex comprising a detectable label;

(3) detecting the detectable label of each bound first complementary nucleic acid molecule or of each first complementary nucleic acid molecule of each first reporter complex,

(4) identifying the position and identity of a plurality of first nucleotides in the immobilized target nucleic acid hybridized by sequencing probes in the first population;

(5) contacting each first attachment region of each sequencing probe of the first population with a plurality first hybridizing nucleic acid molecules each lacking a detectable label thereby unbinding the first complementary nucleic acid molecules comprising a detectable label or the first complementary nucleic acid molecules of each first reporter complex and binding to each first attachment region a first hybridizing nucleic acid molecule lacking a detectable label;

(6) binding to a second attachment region in each sequencing probe in the first population a plurality of second complementary nucleic acid molecules each comprising a detectable label or a plurality of second complementary nucleic acid molecules of a plurality of second reporter complexes each complex comprising a detectable label;

(7) detecting the detectable label of each bound second complementary nucleic acid molecule or of each second complementary nucleic acid molecule of each second reporter complex,

(8) identifying the position and identity of a plurality of second nucleotides in the immobilized target nucleic acid hybridized by sequencing probes in the first population; and

(9) repeating steps (5) to (8) until each nucleotide in the immobilized target nucleic acid corresponding to the target binding domain of each sequencing probe in the first population has been identified.

155. The method of claim 154, wherein conditions that de-hybridize each sequencing probe in the first population from the immobilized target nucleic acid comprise one or more of addition of

a chaotropic agent, a reducing agent, a change in pH, a change in salt concentration, a change of temperature, or a hydrodynamic force.

156. The method of claim 155, wherein the chaotropic agent is selected from the group consisting of butanol, ethanol, guanidinium chloride, lithium acetate, lithium perchlorate, magnesium chloride, phenol, propanol, sodium dodecyl sulfate, lithium dodecyl sulfate, formamide, thiourea, and urea.

157. The method of claim 155, wherein the reducing agent is selected from the group consisting of TCEP (tris(2-carboxyethyl)phosphine), DTT (dithiothreitol) and β -mercaptoethanol.

158. The method of claim 155, wherein the change in temperature is an increase in temperature.

159. The method of 154, wherein steps (5) and (6) occur sequentially or concurrently.

160. The method of claim 154 or claim 159, further comprising steps of:

(10) de-hybridizing each sequencing probe of the first population of sequencing probes from the nucleic acid;

(11) removing each de-hybridized sequencing probe of the first population;

(12) hybridizing at least a second population of sequencing probes to the immobilized target nucleic acid, wherein each sequencing probe in the second population comprises:

a target binding domain and a barcode domain;

wherein said target binding domain comprises at least four nucleotides and is capable of binding a target nucleic acid;

wherein said barcode domain comprises a synthetic backbone, said barcode domain comprising a first attachment region, said first attachment region comprising a nucleic acid sequence capable of being bound by a first RNA molecule and wherein said nucleic acid sequence of said first attachment region determines the position and identity of a first nucleotide in said target nucleic acid that is bound by a first nucleotide of said

target binding domain and

said barcode domain comprising at least a second attachment region, said second attachment region comprising a nucleic acid sequence capable of being bound by a second complementary nucleic acid molecule and wherein said nucleic acid sequence of said second attachment region determines the position and identity of a second nucleotide in said target nucleic acid that is bound by a second nucleotide of said target binding domain and wherein the first complementary nucleic acid molecule is different from the second complementary nucleic acid molecule;

wherein each sequencing probe in the second population de-hybridizes from the immobilized target nucleic acid under about the same conditions; and de-hybridizes from the immobilized target nucleic acid under different conditions than the sequencing probes in the first population;

(13) binding to a first attachment region in each sequencing probe in the second population a plurality of first complementary nucleic acid molecules each comprising a detectable label or a plurality of first complementary nucleic acid molecules of a plurality of first reporter complexes each complex comprising a detectable label;

(14) detecting the detectable label of each bound first complementary nucleic acid molecule or of each first complementary nucleic acid molecule of each first reporter complex,

(15) identifying the position and identity of a plurality of first nucleotides in the immobilized target nucleic acid hybridized by sequencing probes in the second population;

(16) contacting each first attachment region of each sequencing probe of the second population with a plurality first hybridizing nucleic acid molecules lacking a detectable label thereby unbinding the first complementary nucleic acid molecules comprising a detectable label or the first complementary nucleic acid molecules of each first reporter complex and binding to each first attachment region a first hybridizing nucleic acid molecule lacking a detectable label;

(17) binding to a second attachment region in each sequencing probe in the second population a plurality of second complementary nucleic acid molecules each comprising a detectable label or a plurality of second complementary nucleic acid molecules of a plurality of second reporter complexes each complex comprising a detectable label;

(18) detecting the detectable label of each bound second complementary nucleic acid molecule or of each second complementary nucleic acid molecule of each second reporter

complex;

(19) identifying the position and identity of a plurality of second nucleotides in the immobilized target nucleic acid hybridized by sequencing probes in the second population; and

(20) repeating steps (16) to (20) until each nucleotide in the immobilized target nucleic acid and corresponding to the target binding domain of each sequencing probe in the second population has been identified.

161. The method of 160, wherein steps (16) and (17) occur sequentially or concurrently.

162. The method of claim 160 or claim 161, wherein conditions that de-hybridize each sequencing probe in the second population from the immobilized target nucleic acid comprise one or more of addition of a chaotropic agent, a reducing agent, a change in pH, a change in salt concentration, a change of temperature, or a hydrodynamic force.

163. The method of claim 162, wherein the chaotropic agent is selected from the group consisting of butanol, ethanol, guanidinium chloride, lithium acetate, lithium perchlorate, magnesium chloride, phenol, propanol, sodium dodecyl sulfate, thiourea, and urea.

164. The method of claim 162, wherein the reducing agent is selected from the group consisting of TCEP (tris(2-carboxyethyl)phosphine), DTT (dithiothreitol) and β -mercaptoethanol.

165. The method of claim 162, wherein the change in temperature is an increase in temperature.

166. The method of any of claims 160 to 165, wherein each sequencing probe in the second population de-hybridizes from the immobilized target nucleic acid at a higher temperature than the average temperature that the sequencing probes in the first population de-hybridize from the target nucleic acid.

167. The method of claim 166, wherein steps (10) to (20) are repeated with one or more additional populations of probes.

168. The method of claim 167, further comprising steps of assembling each identified linear order of nucleotides for each region of the immobilized target nucleic acid, thereby identifying a sequence for the immobilized target nucleic acid.

169. The method of claim 168, wherein steps of assembling comprise a non-transitory computer-readable storage medium with an executable program stored thereon, wherein the program instructs a microprocessor to arrange each identified linear order of nucleotides for each region of the target nucleic acid, thereby obtaining the sequence of the nucleic acid.

170. The method of any of claims 154 to 169, wherein a population of sequencing probes comprises additional sequencing probes directed to a specific region of interest in the target nucleic acid.

171. The method of claim 170, wherein the region of interest comprises a mutation or a SNP allele.

172. The method of claim 170, wherein the region of interest does not comprises of a known mutation or a SNP allele.

173. The method of any of claims 154 to 172, wherein a population of sequencing probes comprises fewer sequencing probes directed to a specific region not of interest in the target nucleic acid.

174. The method of any of claims 154 to 173, wherein the lengths of target binding domains in a population of sequencing probes is reduced to increase coverage of probes in a specific region of a target nucleic acid.

175. The method of any of claims 154 to 174, wherein the lengths of target binding domains in a population of sequencing probes is increased to decrease coverage of probes in a specific region of a target nucleic acid.

176. The method of any of claims 154 to 175, wherein a population of sequencing probes is compartmentalized into discrete smaller pools of sequencing probes.

177. The method of claim 176, wherein the compartmentalization is based on predicted melting temperature of the target binding domain in the sequencing probes.

178. The method of claim 176, wherein the compartmentalization is based on sequence motif of the target binding domain in the sequencing probes.

179. The method of claim 176, wherein the compartmentalization is based on empirically-derived rules.

180. The method of any of claims 176 to 179, wherein the different pools of sequencing probes can be reacted with the target nucleic acid using different reaction conditions.

181. The method of claim 180, wherein the reaction condition is based on temperature.

182. The method of claim 180, wherein the reaction condition is based on salt concentration.

183. The method of claim 180, wherein the reaction condition is based on buffer content.

184. The method of any of claims 176 to 183, wherein a compartmentalization is performed to cover target nucleic acid with uniform coverage.

185. The method of any of claims 176 to 183, wherein a compartmentalization is performed to cover target nucleic acid with known coverage profile.

186. The method of any of claims 154 to 185, wherein the target nucleic acid is between about 4 and 1,000,000 nucleotides in length up to the length of an intact chromosome or a fragment thereof.

187. The method of any of claims 154 to 186, wherein an attachment region comprises one to fifty copies of a nucleic acid sequence.

188. The method of claim 187, wherein the attachment region comprises two to thirty copies of the nucleic acid sequence.

189. The method of any of claim 154 to 188, wherein the sequencing probe comprises multiple copies of the target binding domain operably linked to a synthetic backbone.

190. The method of any of claim 82 to 189, wherein the rate at which a complementary nucleic acid molecule is unbound from a sequencing probe is accelerated *via* contact of the sequencing probe with hybridizing nucleic acid molecule lacking a detectable label.

191. The method of any of claims 154 to 190, wherein when a first aliquot of a population of probes is de-hybridized from the target nucleic acid and a second aliquot of the population of probes is hybridized to the target nucleic acid, the second aliquot of the population of probes has not previously been hybridized to the target nucleic acid.

192. An apparatus for performing the method of any of claims 82 to 191.

193. The apparatus of claim 192 comprising a consumable sequencing card as shown in Figure 24.

194. A kit comprising a substrate, a plurality of sequencing probes of any of claims 1 to 81, at least one capture probe, at least one complementary nucleic acid molecule comprising a detectable label, at least one complementary nucleic acid molecule which lacks a detectable label, and instructions for use.

195. The kit of claim 193, further comprising a consumable sequencing card as shown in Figure 24.




Figure 1

Figure 2




Figure 3





Figure 4



50
60
70
80
90
100





Figure 6A



65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890




Figure 6C




Figure 6D




Figure 7




Figure 8A




Figure 8B





Figure 8D



W
∞
a
J
J
b
W
L




Figure 9A





Figure 9B



18/42






Figure 9C

Figure 9D








Figure 9G




Figure 10





Figure 11

	Domain	(Optional) dsDNA spacer	Flank 1	AR-1/ Flank 2	AR- 2	AR-2/ Flank 3	AR-3	AR-3/ Flank 4	AR-4	AR-4/ Flank 5
V2 Design	TTCACGTGTA	CTGTCTCATTTTGGCTGCATCCTGTCCGGTTCACGTTG	GAGCTT	GTCATC	CGTCCT	CTTTTC	ACTCCT	AGGCAT	TTGGCCT	ATTGGG
										CGTCCT

...






Figure 13





Figure 14



28/42

Cycling calculator based on probe occupancy

Total # of single molecule targets on flow-cell	30000	
Average length of 'gapped' target (bp)	100	
Barcode occupancy (%) per seq cycle	0.75	
# of barcode cycle required to 'hit' >95% of targets on flow-cell at least once	3	
Dye occupancy (%) per position	0.8	
Total number of Dye positions	6	
Total # of 1 bp encoded read per seq cycle	6	35
Total # of 2 bp encoded read per seq cycle	23	346
Total # of 3 bp encoded read per seq cycle	92	1843
Total # of 4 bp encoded read per seq cycle	369	5530
Total # of 5 bp encoded read per seq cycle	1475	8847
Total # of 6 bp encoded read per seq cycle	5898	5898
Total number of 'usable' read per seq cycle		22499
# of barcode cycle required to cover given single molecule target with ~3X coverage	143	
# of barcode cycle required to cover given single molecule target with ~5X coverage	238	
# of barcode cycle required to cover all single molecule target on flow-cell with ~3X coverage	430	
# of barcode cycle required to cover all single molecule target on flow-cell with ~5X coverage	713	

Figure 15

	Gigabases	time hrs.	# Reads	Clinical utility
HiSeq 2500	900Gb	11 days	3 Billion !	Genome sequence cancer sequence
Next Seq	120GB	27hrs	400M	Genome sequence exome Transcriptome
Proton PI	10Gb	2-4	70M	exome Transcriptome
Present Invention	3 to 12 Gb	3	0.5M	Targeted (Dx, cDx) plus multi-analyte plus sample-to-answer, long-reads
MiSeq	3.5Gb	24hrs	25M	transcriptome targeted (Dx)
PGM 318	up to 2Gb	7.3/4.4	4M	Targeted
PacBio RS II	2.2Gb/day	3 hrs	50k	Niche genomes, long-reads, high error rate
PGM 314	0.1Gb	3.7/2.3	400k	Targeted

Figure 16

Figure 17




Figure 18





Figure 19




* Counts observed value represent counts after background count subtraction
**All hybridization done under buffer condition: 1xSSPE/0.1% Tween20

33/42


Figure 20A

5x5


(1 primary nucleic acid molecule, 5 secondary nucleic acid molecules, 5 tertiary nucleic acid molecule with detectable label(s))



4x3



3x4



Spacer 3x4




Figure 20B




Figure 20C

Exemplary recipe for constructing reporter complexes comprising detectable labels

Volume (uL)	Primary n. a. molecule (10uM)	Secondary n. a. molecule (10uM)	Tertiary n. a. molecule (100uM)	H2O
5x4	1	4.5	2.25	92.25
5x3	1	4.5	1.8	92.7
4x4	1.28	4.5	2.25	91.97
4x3	1.28	4.5	1.8	92.42
3x4	1.8	4.5	2.25	91.45

Colors in table correspond to colors in diagrams of complexes shown at left




Figure 21A




Figure 21B

Figure 22A




Figure 22B

'7x3 extra handles' Kinetics





Figure 23






Figure 24

Figure 25

code	sequences
YGBYGR	GAGACTGTAC - original
BGYRGB	GAGACAGTAC
YBRYGB	GAGACCGTAC
RGBYGR	GAGACGGTAC
YRBGYR	GAGAGTGTAC
GRYGRB	GAGAATGTAC
RGYBRG	GAGATTGTAC

code	counts	sequences
YGBYGR	16074	GAGACTGTAC
RGYBRG	1132	GAGATTGTAC
YBRYGB	998	GAGACCGTAC
YRBGYR	784	GAGAGTGTAC
YBRYBG	712	
YBGRBY	699	
YGRYBG	692	
YBRGBR	674	
Background Threshold	717	

Figure 26

DNA	Sequence	code	count
12 mer	CTGAGACTGTAC	RYGBRG	80845
11 mer	TGAGACTGTAC	GBRYGB	24474
10 mer	GAGACTGTAC	YGBYGR	18339
9 mer	AGACTGTAC	YRBYRG	1667
Mirror of "12 mer"	CATGTCAGAGTC	GRBGYR	1473
Mirror of "11 mer"	CATGTCAGAGT	BGYRBG	1384
8 mer	GACTGTAC	GBRYBG	900
		Background Threshold	622

Figure 27

Full length Reporter
20 *pM* full length (6 spot) 33 counts/fov

Single Spot Reporter	Counts/FOV
Single spot [fM]	Saturated
20,000	12000
2,000	
200	308
20	40
2	11

20pM NS reporter \approx 20fM Single spot

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/061615

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12Q1/68
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EP0-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2013/055995 A2 (HARVARD COLLEGE [US]) 18 April 2013 (2013-04-18) the whole document Fig. 1, 2; para. 4, 36-37, 113, 143-139,184	1-195
X	----- US 7 745 129 B1 (SCHATZ KENNETH DAVID [US]) 29 June 2010 (2010-06-29) the whole document Fig. 1-3, 18, 19; col. 1-32, 24, 35, 38; claim 6	1-195
A	----- US 2014/005067 A1 (WEBSTER PHILIPPA JANE [US] ET AL) 2 January 2014 (2014-01-02) cited in the application the whole document Fig. 1, para. 6, 7 -----	1-195



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 January 2016

Date of mailing of the international search report

08/02/2016

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Sauer, Tincuta

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2015/061615

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2013055995 A2	18-04-2013	CA 2850509 A1 EP 2766498 A2 JP 2014531908 A US 2014349294 A1 WO 2013055995 A2	18-04-2013 20-08-2014 04-12-2014 27-11-2014 18-04-2013
US 7745129 B1	29-06-2010	NONE	
US 2014005067 A1	02-01-2014	AU 2009281836 A1 CA 2733609 A1 EP 2331704 A1 JP 5836803 B2 JP 2012500007 A JP 2015130880 A US 2010047924 A1 US 2014005067 A1 WO 2010019826 A1	18-02-2010 18-02-2010 15-06-2011 24-12-2015 05-01-2012 23-07-2015 25-02-2010 02-01-2014 18-02-2010